RESEARCH POSTER PRESENTATIONS SESSION IV: Tuesday, 6 November 2012

Click on the topic below to view posters

SESSION IV – TUESDAY, 6 NOVEMBER
SET-UP: Tuesday, 6 November, 14:45 – 15:00
POSTER DISPLAY HOURS: Tuesday, 6 November,15:00-19:00
POSTER AUTHOR DISCUSSION HOUR: Tuesday, 6 November, 18:00 – 19:00
DISMANTLE: Tuesday, 6 November, 19:00

RESEARCH ON METHODS – Clinical Outcomes Methods

PRM1

KAPLAN-MEIER SURVIVAL CURVES: A POTENTIAL SOURCE OF DATA FOR SYSTEMATIC REVIEWS

 

Gupta J, Bhutani MK, Kumar R, Kaur M, Jindal R, Siddiqui MK
Heron Health Private Ltd., Chandigarh, Chandigarh, India

PRM2

ASSESSING RELATIVE CLINICAL VALUE WITHIN THREE METASTATIC DISEASES

 

Karweit J1, Wolfe S1, Kotapati S2, Lees M3, Abernethy AP4
1IMS Consulting Group, New York, NY, USA, 2Bristol-Myers Squibb Pharmaceuticals, Wallingford, CT, USA, 3Bristol-Myers Squibb, Rueil-Malmaison, France, 4Duke Clinical Research Institute and Duke Cancer Institute, Durham, NC, USA

PRM3

TURNING THE TABLES TO ADDRESS THE REAL VALUE OF REAL-WORLD OBSERVATIONAL STUDIES OF NOVEL ANTI-CANCER AGENTS IN MULTIPLE MYELOMA

 

Gaultney JG1, Franken MG1, Redekop WK1, Huijgens PC2, Uyl-de Groot CA1, Sonneveld P3
1Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands, 2VU University Medical Center, Amsterdam, The Netherlands, 3Erasmus Medical Center, Rotterdam, The Netherlands

PRM4

ASSESSMENT OF IMMUNOSUPPRESSIVE THERAPIES FOR RENAL TRANSPLANTATION - CRITERIA CONSIDERED FOR EVALUATION BY THE EMA, EUROPEAN HTA AGENCIES AND THE GERMAN IQWIG

 

Claus V1, Moser S1, Mathes J2, Kotowa W2
1Novartis Pharma GmbH, Nuremberg, Germany, 2IGES Institut GmbH, Nuremberg, Germany

PRM5

ATTRIBUTION OF BENEFIT TO THE THREE DISEASE DIMENSIONS MORTALITY, MORBIDITY, QUALITY OF LIFE WITHIN EARLY BENEFIT ASSESSMENT (EBA) IN GERMANY

 

Ruof J1, Martin DD2, Schwartz F3
1Roche Pharma, Grenzach-Wyhlen, Germany, 2University of Tuebingen, Tuebingen, Germany, 3Hannover Medical School, Hannover, Germany

PRM6

THE UK CONTRIBUTION TO REAL WORLD RESEARCH: REVIEW OF PUBLISHED DATA AT ISPOR, MADRID 2011

 

Peperell K1, Lones R2, Devlin N3
1pH Associates, Marlow, UK, 2Bristol-Myers Squibb, Uxbridge, Middlesex , UK, 3Office of Health Economics, London, UK

PRM7

INCREASING PHYSICAL ACTIVITY IN PATIENTS WITH CHRONIC DISEASE: WHAT IS THE LITERATURE TELLING US?

 

Leidy NK1, Kimel M1, Ajagbe L1, Kim K1, Hamilton A2, Becker K3
1United BioSource Corporation, Bethesda, MD, USA, 2Boehringer Ingelheim (Canada) Ltd., Burlington, ON, Canada, 3Boehringer Ingelheim GmbH, Ingelheim/Rhein, Germany

PRM8

TREATMENT OF RHEUMATOID ARTHRITIS – COMPARATIVE EFFECTIVENESS OF BIOLOGICS

 

Schiffner-Rohe J1, Leverkus F1, Behmer OS2, Kerkmann U2
1Pfizer Deutschland GmbH, Berlin, Germany, 2Pfizer Pharma GmbH, Berlin, Germany

PRM9

USING PROPENSITY SCORE MATCHING TO ESTIMATE THE RESOURCE BURDEN OF HOSPITAL ACQUIRED CLOSTRIDIUM DIFFICILE INFECTION IN ENGLAND

 

Wasserman M1, Cylus J2, Latif F1, Roberts G3
1Double Helix Consulting, London, UK, 2European Observatory on Health Systems and Policies & London School of Economics and Political Science, London , UK, 3Double Helix Consulting Group, London, UK

PRM10

USE OF VA DATABASES FOR RETROSPECTIVE STUDIES IN ULCERATIVE COLITIS OUTCOMES RESEARCH

 

Koleva YN1, Shi L2, Abbas A3, Khan N4
1Tulane University / Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA, 2Tulane University, New Orleans, LA, USA, 3Tulane University / Southest Louisiana Veterans Health Care System, New Orleans , LA, USA, 4Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA

PRM11

REAL-WORLD DATA TO CALCULATE COST-EFFECTIVENESS OF MONOCLONAL ANTIBODIES: PROBLEMS AND SOLUTIONS

 

van Rooijen EM, van der Linden N, van Gils C, Oppe M, Uyl-de Groot C
Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands

PRM12

JOINT ESTIMATION OF PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL

 

Ouwens MJ1, Bergman G2
1MAPI Consultancy, Houten, The Netherlands, 2MAPI Consultancy, Houten, The Netherlands

PRM13

METHODS FOR ESTIMATING SURVIVAL BENEFITS IN THE PRESENCE OF TREATMENT CROSSOVER: A SIMULATION STUDY

 

Latimer N1, Lambert P2, Crowther M2, Abrams KR2, Wailoo AJ1, Morden JP3
1University of Sheffield, Sheffield, UK, 2University of Leicester, Leicester, UK, 3The Institute of Cancer Research, Sutton, Surrey, UK

RESEARCH ON METHODS – Cost Methods

PRM14

EUROPEAN ASSESSMENT OF THE VALIDITY OF THE QALY OUTCOME MEASURE: RESULTS FROM THE EXPERIMENT CONDUCTED BY THE ECHOUTCOME PROJECT

 

Beresniak A1, Auray J2, Duru G3, Medina-Lara A4, Tarricone R5, Sambuc R6, Torbica A7, Lamure M8, Echoutcome Study Group -9
1Data Mining International, Geneva, Switzerland, 2Cyklad Group, Rilleux la Pape, France, 3Cyklad Group, rilleux la Pape, France, 4Bocconi University, Mialno, Ivory Coast, 5Bocconi University, Milano, Italy, 6Université de la Mediterrannee, Marseille, France, 7Bocconi University, Milan, Italy, 8University Claude Bernard Lyon 1, Lyon cedex 08, Rhone Alpes, France, 9Echoutcome European Project, Brussels, Belgium

PRM15

ASSESSING THE BROADER IMPACT OF VACCINATIONS: A GOVERNMENT PERSPECTIVE QUANTITATIVE ANALYTIC FRAMEWORK APPLIED TO VACCINATION

 

Kotsopoulos N1, Connolly M2, Postma M3, Hutubessy R4
1Unit of PharmacoEpidemiology & PharmacoEconomics, Groningen, The Netherlands, 2University of Groningen, Groningen, The Netherlands, 3University of Groningen, Groningen, Groningen, The Netherlands, 4World Health Organization, Geneva, Geneva, Switzerland

PRM16

ACCESS TO COST DATA CAPTURE USING PUBLIC DATABASE, WEBSITE AND LITERATURE IN GERMANY, FRANCE, SPAIN AND USA

 

Alvarez-Ossorio L1, Ezzat N1, Cariou Y1, Tarab A2
1Boston Healthcare Associates International GmbH, Berlin, Germany, 2Boston Healthcare Associates, Inc., Boston, MA, USA

PRM17

ECONOMIC EVALUATION OF VACCINES: CONSIDERATIONS ON EVIDENCE, DISCOUNTING, MODELS AND FUTURES CHALLENGES

 

Postma M1, Largeron N2, Annemans L3
1Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen, Groningen , The Netherlands, 2Sanofi Pasteur MSD, Lyon, France, 3Ghent University & Brussels University, Ghent, Belgium

PRM18

CONDUCTING PHARMACEUTICAL BUDGET IMPACT ANALYSES IN IRAN: IN ACCORDANCE WITH ISPOR TASK FORCE REPORT ON GOOD PRACTICE FOR BUDGET IMPACT ANALYSIS

 

Foroutan N1, Jamshidi HR1, Salamzadeh J1, Foroutan A2, Rasekh H1
1Shahid Beheshti University of Medical Sciences, Tehran, Iran, 2Tehran University of Medical Sciences, Tehran, Iran

PRM19

SOMETHING FOR NOTHING? THE VALUE OF INFORMAL CARE

 

Faria R, Weatherly H, van den Berg B
University of York, York, North Yorkshire, UK

PRM20

EMPIRICAL ANALYSIS SHOWS REDUCED COST DATA COLLECTION MAY BE AN EFFICIENT METHOD IN ECONOMIC CLINICL TRIALS

 

Seidl H
Helmholtz Zentrum München, Neuherberg, Germany

PRM21

COMMUNICATING TO DECISION MAKERS THE PARAMETER UNCERTAINTY IN THE IQWIG EFFICIENCY FRONTIER APPROACH

 

Stollenwerk B1, Briggs A2, Fenwick E2, Caro JJ3, Siebert U4, Lhachimi SK5, Gerber A6
1Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany, 2University of Glasgow, Glasgow, UK, 3United BioSource Corporation, Montreal, QC, Canada, 4UMIT/ Oncotyrol/ Harvard University, Hall i.T.;Innsbruck, Tyrol, Austria, 5Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany, 6Institute of Quality and Efficiency in Health Care (IQWiG), Köln, Germany

PRM22

THE HEADROOM METHOD OF EARLY ECONOMIC EVALUATION OF MEDICAL DEVICES: A USEFUL TOOL FOR DEVICE DEVELOPERS?

 

Chapman AM, Taylor CA, Girling AJ
University of Birmingham, Birmingham, West Midlands, UK

PRM23

COST-EFFECTIVENESS VERSUS PATIENT ACCEPTABILITY: THE EXEMPLAR OF CFS/ME

 

Richardson G1, Epstein D2, Wearden A3
1University of York, York, UK, 2University of York, York, York, UK, 3University of Manchester, Manchester, UK

PRM24

METHODS FOR ANALYSIS OF CENSORED COST DATA

 

Jönsson L
OptumInsight, Stockholm, Sweden

PRM25

ISSUES AND UNCERTAINTIES IN COMBINATIONS OF DIAGNOSTIC TECHNOLOGIES: A CASE STUDY IN EPILEPSY SURGERY

 

Hinde S, Soares MO, Palmer S
University of York, York, North Yorkshire, UK

RESEARCH ON METHODS – Databases & Management Methods

PRM26

THE USE OF CLAIMS-BASED CHA2DS2-VASC AND ATRIA SCORES TO PREDICT STROKE/SYSTEMIC EMBOLISM AND BLEEDING RATES AMONG ANTICOAGULATED PATIENTS WITH ATRIAL FIBRILLATION (AFIB) IN A PHARMACY-BENEFIT MANAGEMENT (PBM) ENVIRONMENT

 

Malone DC1, Charland SL2, Agatep BC2, Herrera V2, Hawk GS2, Schrader BJ2, Stanek EJ2
1University of Arizona, Tucson, AZ, USA, 2Medco Research Institute, LLC/an Express Scripts Company, Bethesda, MD, USA

PRM27

EVALUATING EUROPEAN DATA SOURCES FOR ASSESSING REAL-WORLD EFFECTIVENESS OF NEW ANTI-DIABETIC DRUGS

 

Moïse P1, Andreykiv M2, Van Engen A2, Wimbush AJ3, Richards A3, Ploug UJ4
1Quintiles Global Consulting, Levallois-Perret, Ile-de-France, France, 2Quintiles Global Consulting, Hoofddorp, Noord-Holland, The Netherlands, 3Novo Nordisk A/S, Zurich Oerlikon, Switzerland, 4Novo Nordisk A/S, Søborg, Denmark

PRM28

ASSESSING THE COMPLETENESS OF MATERNITY DATA RECORDING IN UK PRIMARY AND SECONDARY CARE

 

Man SL1, Petersen I1, Nazareth I1, Bourke A2, Thompson M2
1University College London, London, UK, 2Cegedim Strategic Data Medical Research Ltd, London, UK

PRM29

SUPRAPUBIC PROSTATECTOMY (SP) VERSUS TRANSURETHRAL ENDOSCOPIC RESECTION OF PROSTATE (TURP): HOSPITALIZATION OUTCOMES AND COSTS OF BENIGN PROSTATIC HYPERPLASIA USING A PRUBLIC DATABASE (DATASUS) IN BRAZIL

 

Barbosa EG, Lowery AP, Santos PA, Machado M
GlaxoSmithKline Ltda, Rio de Janeiro, Rio de Janeiro, Brazil

PRM30

HOSPITALIZATION REGISTRY AND COSTS OF BENIGN PROSTATIC HYPERPLASIA PATIENTS (BPH) BASED ON A PUBLIC DATABASE (DATASUS) IN BRAZIL

 

Barbosa EG, Lowery AP, Santos PA, Machado M
GlaxoSmithKline Ltda, Rio de Janeiro, Rio de Janeiro, Brazil

PRM31

ASSESSMENT OF ADOPTION OF U.S. PRESCRIBING GUIDELINES FOR DABIGATRAN IN A REAL WORLD POPULATION

 

Schrader BJ1, Charland SL1, Malone DC2, Agatep BC1, Herrera V1, Hawk GS1, Stanek EJ1
1Medco Research Institute, LLC/an Express Scripts Company, Bethesda, MD, USA, 2University of Arizona, Tucson, AZ, USA

PRM32

DEVELOPMENT OF A POST-MARKETING REQUIREMENTS (PMR) DATABASE

 

Mouchet J1, Emery MP1, Maier W2
1MAPI Research Trust, Lyon, France, 2Registrat-Mapi, London, UK

PRM33

REAL WORLD EVIDENCE: PROMISE AND PITFALLS OF REAL WORLD DATA

 

Weir S1, Langham S1, Ratcliffe M2
1PHMR Associates Ltd, London, UK, 2PHMR Associates, London, UK

PRM34

ROUTINE DATA IN HTA: RECORD LINKAGE IN AUSTRIAS GAP-DRG DATABASE

 

Endel F1, Endel G2, Pfeffer N2
1Vienna University of Technology, Klosterneuburg, Noe, Austria, 2Main Association of Austrian Social Security Institutions, Vienna, Austria

PRM35

PREVALENCE OF RARE DISEASES – A SPECIAL CHALLENGE FOR BENEFIT ASSESSMENT AND HEALTH ECONOMICS

 

Schmitt D1, Schiffner-Rohe J2, Brösamle C3
1Pfizer Pharma GmbH, Berlin, Germany, 2Pfizer Deutschland GmbH, Berlin, Germany, 3Avanced Medical Services, München, Germany

PRM36

PATIENT-REPORTED OUTCOME AND QUALITY OF LIFE INSTRUMENTS DATABASE (PROQOLID): EVOLUTION OF CONTENT, STRUCTURE, AND FUNCTIONALITIES (2002-2012)

 

Emery MP, Caron M, Perrier LL
MAPI Research Trust, Lyon, France

PRM37

INDIRECT IDENTIFICATION OF PAYER PERCEPTIONS THROUGH RETROSPECTIVE ANALYSIS OF INTERVIEW WRITE-UPS

 

Ruppert A, King Z, Petrie N, Rao N, Plata A
IMS Consulting Group, Cambridge, UK

PRM38

ESTIMATION OF A MARKOV CHAIN FOR CROHN'S DISEASE AND CLASSIFICATION OF PATIENTS INTO DISEASE PHENOTYPES, IN EIGHT COUNTRIES USING INDIVIDUAL LONGITUDINAL DATA AGGREGATED OVER TIME

 

Borg S1, Gerdtham UG2, Rydén T3, Munkholm P4, Odes S5, Langholz E6, Moum B7, Annese V8, Bagnoli S9, Beltrami M10, Clofent J11, Friger M12, Milla M13, Mouzas I14, O'Morain C15, Politi P16, Riis L4, Stockbrugger R17, Tsianos E18, Vardi H12, Lindgren S19
1The Swedish Institute for Health Economics, Lund, Sweden, and Faculty of Medicine, Lund University, Lund, Sweden, Lund, Sweden, 2Department of Economics, Lund University, Lund, Sweden, and Faculty of Medicine, Lund University, Lund, Sweden, 3Royal Institute of Technology, Stockholm, Sweden, 4Herlev Hospital and University of Copenhagen, Copenhagen, Denmark, 5Soroka Medical Center, Beer-Sheva, Israel, 6Gentofte Hospital and University of Copenhagen, Hellerup, Denmark, 7Oslo University Hospital & University Oslo, Oslo, Norway, 8University Hospital Careggi, Florence, Italy, 9Firenze, Florence, Italy, 10Reggio Emilia, Rome, Italy, 11Hospital Meixoeiro, Vigo, Spain, 12Ben Gurion University of the Negev, Beer-Sheva, Israel, 13University Hospital Carreggi, Florence, Italy, 14Crete University, Heraklion, Greece, 15Trinity Centre for Health Sciences, Dublin, Ireland, 16Istituti Ospitalieri di Cremona, Cremona, Italy, 17University Hospital Maastricht, Maastricht, The Netherlands, 18University of Ioannina, Ioannina, Greece, 19Lund University, Malmö, Sweden

PRM39

EVALUATION OF PATIENT CENTERED OUTCOMES USING INDIVIDUAL DATA FROM A QUALITY REGISTRY AND PATIENT REPORTED ABILITIES AND RATINGS OF QUALITY IN HEALTH CARE, IN DIABETES PATIENTS IN SWEDEN

 

Borg S1, Palaszewski B2, Gerdtham UG3, Ödegaard F4, Gudbjörnsdottir S2
1The Swedish Institute for Health Economics, Lund, Sweden, and Faculty of Medicine, Lund University, Lund, Sweden, Lund, Sweden, 2Nationella Diabetesregistret NDR, Gothenburg, Sweden, 3Department of Economics, Lund University, Lund, Sweden, and Faculty of Medicine, Lund University, Lund, Sweden, 4University of Western Ontario, London, ON, Canada

PRM40

EFFICACY OF LIRAGLUTIDE COMPARED TO EXENATIDE AND INSULIN GLARGINE IN PATIENTS WITH DIABETES TYPE 2: A META-ANALYSIS

 

Fadipe JJ
University of Wolverhampton, Wolverhampton, West Midlands, UK

PRM41

DESIGNING PATIENT REGISTRIES: A CASE-STUDY USING AN ONLINE INTERACTIVE DATA ANALYSIS TOOL

 

Foley K1, Patel AM2, Long S1, Benson C3
1Thomson Reuters Healthcare, Cambridge, MA, USA, 2Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 3Janssen Scientific Affairs, LLC, Titusville, NJ, USA

PRM42

MANAGING A SYSTEMATIC LITERATURE REVIEW PROJECT

 

Kiss N, Sidhu M, Tongbram V
Oxford Outcomes, Morristown, NJ, USA

RESEARCH ON METHODS – Modeling Methods

PRM43

A SYSTEMATIC REVIEW ON THE APPLICATION OF CARDIOVASCULAR RISK PREDICTION MODELS IN PHARMACOECONOMICS, WITH A FOCUS ON PRIMARY PREVENTION

 

Stevanovic J, Postma MJ, Pechlivanoglou P
University of Groningen, Groningen, The Netherlands

PRM44

INCREASING LIFE EXPECTANCY: IMPLICATIONS FOR COST-EFFECTIVENESS ANALYSIS

 

Majer IM, Heeg B
Pharmerit International, Rotterdam, Zuid-Holland, The Netherlands

PRM45

WITHDRAWN

 

 

PRM46

DEVELOPMENT OF A FRAMEWORK FOR COST-EFFECTIVENESS ANALYSIS COHORT SIMULATION USING AN ORDINARY DIFFERENTIAL EQUATION SOLVER ALGORITHM IN R

 

Frederix GW1, van Hasselt JG2, Severens JL3, Hövels AM4, Huitema AD5, Raaijmakers JA6, Schellens JH7
1Netherlands Cancer Institute, Amsterdam, The Netherlands 2Slotervaart Hospital/Netherlands Cancer Institute, Amsterdam, The Netherlands 3Erasmus University Rotterdam, Rotterdam, The Netherlands, 4Utrecht University, Utrecht, The Netherlands, 5Slotervaart Hospital/Netherlands Cancer Institute, Amsterdam, The Netherlands, 6Utrecht University & GlaxoSmithKline, Utrecht, The Netherlands, 7Netherlands Cancer Institute & Utrecht University, Amsterdam, The Netherlands

PRM47

COST-EFFECTIVENESS UNCERTAINTY ANALYSIS METHODS: A COMPARISON OF ONE-WAY SENSITIVITY, ANALYSIS OF COVARIANCE, AND EXPECTED VALUE OF PARTIAL PERFECT INFORMATION

 

Campbell J1, McQueen RB1, Libby AM2, Spackman E3, Carlson J4, Briggs A5
1University of Colorado, Aurora, CO, USA, 2University of Colorado, Denver, Aurora, CO, USA, 3University of York, Heslington, North Yorkshire, UK, 4University of Washington, Seattle, WA, USA, 5University of Glasgow, Glasgow, UK

PRM48

THE HALF-CYCLE “CORRECTION”: HOW MUCH OF A CORRECTION IS IT?

 

Taylor M, Lewis L
University of York, York, UK

PRM49

EQ-5D VERSUS DISEASE-SPECIFIC HR-QOL INSTRUMENTS – NO CONTEST?

 

Ratcliffe AE, Ratcliffe M
PHMR Associates, London, UK

PRM50

RANDOM NUMBER GENERATORS IN MONTE CARLO SIMULATION

 

McEwan P1, Foos V2, Chraibi M3, Lloyd A4, Palmer JL5, Lamotte M6, Grant D4
1HEOR Consulting, Monmouth, Monmouthshire, UK, 2IMS Health, Basel, Basel-Stadt, Switzerland, 3Institute for Advanced Simulation, Jülich, Germany, 4IMS Health, London, UK, 5IMS Health, Allschwil, Basel-Landschaft, Switzerland, 6IMS Health, Vilvoorde, Belgium

PRM51

WITHDRAWN

 

 

PRM52

MINIMUM RUN-TIME REQUIREMENTS TO REDUCE MONTE CARLO ERROR IN STOCHASTIC SIMULATIONS

 

Foos V1, McEwan P2, Lloyd A3, Palmer JL4, Lamotte M5, Grant D3
1IMS Health, Basel, Basel-Stadt, Switzerland, 2HEOR Consulting, Monmouth, Monmouthshire, UK, 3IMS Health, London, UK, 4IMS Health, Allschwil, Basel-Landschaft, Switzerland, 5IMS Health, Vilvoorde, Belgium

PRM53

CAN THE DISUTILITY OF ALLERGIC RHINITIS AND CONJUNCTIVITIS BE CALCULATED FROM THE AGGREGATED TOTAL SYMPTOMS SCORE?

 

Langkilde LK1, Volk J2, Nørgaard Andreasen J3
1Wickstrøm & Langkilde ApS, Vejle, Denmark, 2ALK-abelló Arzneimittel GmbH, Wedel, Germany, 3ALK-abelló A/S, Hoersholm, Denmark

PRM54

CORRELATING COST EFFECTIVENESS OUTPUT WITH PATIENT LEVEL DATA INPUT VIA THE IMS CORE DIABETES MODEL (CDM)

 

McEwan P1, Foos V2, Lloyd A3, Palmer JL4, Lamotte M5, Grant D3
1HEOR Consulting, Monmouth, Monmouthshire, UK, 2IMS Health, Basel, Basel-Stadt, Switzerland, 3IMS Health, London, UK, 4IMS Health, Allschwil, Basel-Landschaft, Switzerland, 5IMS Health Consulting Group, Vilvoorde, Belgium

PRM55

THIRD PARTY MODEL VALIDITY: A REVIEW AND SURVEY OF FACE AND INTERNAL VALIDITY OF HEALTH ECONOMIC MODELS

 

Becker RV
Russell Becker Consulting, Chicago, IL, USA

PRM56

DEVELOPMENT OF A CONCEPTUAL MODEL FOR USE IN ECONOMIC MODELLING OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

 

Gonzalez McQuire S1, Tabberer M1, Muellerova H2, Briggs A3, Lomas D4, Rutten-van Mölken MP5, Chambers M6
1GlaxoSmithKline R&D, Uxbridge, Middlesex, UK, 2GlaxoSmithKline R&D, Uxbridge, UK, 3University of Glasgow, Glasgow, UK, 4University of Cambridge, Cambridge , UK, 5Erasmus University, Rotterdam, The Netherlands, 6GlaxoSmithKline, Brentford, UK

PRM57

DEVELOPING BASDAI AND BASFI PREDICTIVE EQUATIONS FROM CLINICAL TRIAL DATA OF GOLIMUMAB FOR SEVERE, ACTIVE ANKYLOSING SPONDYLITIS IN ADULTS

 

Chaudhary MA1, Hsu B2, Muszbek N3, Proskorovsky I4, Farrell J5
1Merck Research Laboratories, North Wales, PA, USA, 2Janssen R&D, Inc., Spring House, PA, USA, 3United BioSource Corporation, Budapest, Hungary, 4United BioSource Corporation, Dorval, QC, Canada, 5MSD, Hoddesdon, Hertfordshire, UK

PRM58

LONG-TERM VALIDATION OF THE IMS CORE DIABETES MODEL IN TYPE 1 AND TYPE 2 DIABETES

 

Foos V1, Palmer JL2, Grant D3, Lloyd A3, Lamotte M4, McEwan P5
1IMS Health, Basel, Basel-Stadt, Switzerland, 2IMS Health, Allschwil, Basel-Landschaft, Switzerland, 3IMS Health, London, UK, 4IMS Health, Vilvoorde, Belgium, 5HEOR Consulting, Monmouth, Monmouthshire, UK

PRM59

METHODS FOR DISCOUNTING IN ECONOMIC EVALUATION; AN EMPIRICAL COMPARISON OF PREFERENCES IN MONEY AND QUALITY OF LIFE

 

Parouty M1, Krooshof D2, Westra T3, Postma M4
1University of Groningen, Groningen, The Netherlands, 2University of Groningen, Groningen, The Netherlands, 3University Medical Centre Groningen, Groningen, The Netherlands, 4Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen, Groningen , The Netherlands

PRM60

GENERAL METHODOLOGICAL ISSUES IN COST-EFFECTIVENESS ANALYSIS INSPIRED BY THE ASSESSMENT OF DASATINIB, NILOTINIB AND IMATINIB FOR 1ST- LINE CHRONIC MYELOID LEUKAEMIA

 

Hoyle M1, Pavey T1, Ciani O1, Crathorne L1, Jones-Hughes T1, Cooper C1, Osipenko L2, Venkatachalam M3, Rudin C4, Ukoumunne O5, Garside R1, Anderson R1
1University of Exeter, Exeter, Devon, UK, 2Matrix, London, London, UK, 3Matrix, london, london, UK, 4Royal Devon & Exeter Hospital, Exeter, Devon, UK, 5Peninsula Medical School/National Institute for Health Research, Exeter, Devon, UK

PRM61

EXTERNAL VALIDATION OF A CARDIO-VASCULAR DISEASE MODEL

 

Kuehne F1, Conrads-Frank A2, Kuerwitz S3, Jegan N3, Popert U4, Donner-Banzhoff N3, Siebert U5
1Department of Public Health and Health Technology Assessment, UMIT - University for Health Sciences, Hall, Austria, 2UMIT - University for Health Sciences,, Hall i.T., Austria, 3Philipps University, Marburg, Germany, 4Georg-August-University, Goettingen, Germany, 5UMIT/ Oncotyrol/ Harvard University, Hall i.T.;Innsbruck, Tyrol, Austria

PRM62

TIME-DEPENDENCY FOR TREATMENT SEQUENCES: A CASE-EXAMPLE IN EPILEPSY

 

Shah D1, Khan N1, Hawkins N2, Briggs A3
1Oxford Outcomes Ltd., Morristown, NJ, USA, 2Oxford Outcomes, Oxford, UK, 3University of Glasgow, Glasgow, UK

PRM63

LONG-TERM BURDEN OF ASTHMA IN CHILDREN WITH ALLERGIC RHINITIS/ CONJUNCTIVITIS

 

Langkilde LK1, Andersen L2, Nørgaard Andreasen J2
1Wickstrøm & Langkilde ApS, Vejle, Vejle, Denmark, 2ALK-abelló A/S, Hoersholm, Denmark

PRM64

BAYESIAN MTC MODELS TO COMBINE EVIDENCE FROM DIFFERENT TRIAL DESIGNS

 

Schmitz S1, Adams RC2, Barry M3, Walsh C1
1Trinity College Dublin, Dublin, Ireland, 2National Centre for Pharmacoeconomics, Dublin, Ireland, 3St. James's Hospital, Dublin, Ireland, Ireland

PRM65

A MINIMAL INFORMATION DECISION-ANALYTIC APPROACH TO EARLY HTA OF DIAGNOSTIC TESTS

 

Koffijberg H1, Moons KG1, de Wit GA2
1University Medical Center Utrecht, Utrecht, The Netherlands, 2National Institute for Public Health and the Environment, Bilthoven, The Netherlands

PRM66

DISCRETE EVENT SIMULATION: MODELING SIMULTANEOUS COMPLICATIONS AND OUTCOMES

 

Quik EH, Feenstra TL, Krabbe PFM
University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

PRM67

THE USE OF HEALTH ECONOMIC MODELS IN HUNGARIAN HEALTH TECHNOLOGY ASSESSMENT

 

Nemeth B, Borsi A
National Institute for Quality- and Organizational Development in Healthcare and Medicines, Budapest, Hungary

PRM68

COMPARATIVE COMPUTATION SPEED OF EXCEL, VISUAL BASIC FOR APPLICATIONS, R, AND JAVA IN EXECUTION OF A MICROSIMULATION MODEL WITH PROBABILISTIC SENSITIVITY ANALYSIS

 

Snedecor SJ1, Ji X1, Ektare V1, Treur M2
1Pharmerit International, Bethesda, MD, USA, 2Pharmerit International, Rotterdam, The Netherlands

PRM69

NETWORK META-ANALYSIS OF INTERVENTIONS FOR OVERACTIVE BLADDER AND DETRUSOR INSTABILITY – A HIERARCHICAL MODELLING APPROACH

 

Owen RK, Abrams K, Tincello DG
University of Leicester, Leicester, UK

PRM70

WHAT IF ALL OTHER THINGS ARE NOT EQUAL? – ACCOUNTING FOR FUTURE CHANGES IN THE DECISION CONTEXT WHEN EXTRAPOLATING COST-EFFECTIVENESS RESULTS OVER TIME

 

Asaria M, Palmer S
University of York, York, North Yorkshire, UK

PRM71

DIFFERENTIAL TIME PREFERENCE FOR MONEY, LIFE YEARS AND QUALITY OF LIFE: AN EMPIRICAL PILOT STUDY

 

Parouty M1, Krooshof D2, Westra T3, Pechlivanoglou P1, Postma M4
1University of Groningen, Groningen, The Netherlands, 2University of Groningen, Groningen, The Netherlands, 3University Medical Centre Groningen, Groningen, The Netherlands, 4Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen, Groningen , The Netherlands

PRM72

MODEL SELECTION PROCESS FOR COST EFFECTIVENESS ANALYSIS OF AN ORGANIZED AAA SCREENING IN AUSTRIA

 

Urach C1, Zauner G2, Wilbacher I3, Breitenecker F1
1Vienna University of Technology, Vienna, Austria, 2Dwh Simulation Services, Vienna, Austria, 3Main Association of Austrian Social Security Institutions, Vienna, Austria

PRM73

THE USE OF CUMULATIVE HAZARD PLOTS TO INFORM RESOURCE ALLOCATION AND RESEARCH DECISIONS IN HEALTH CARE

 

McNamara S
Roche Products Limited, Welwyn Garden City, UK

PRM74

COST EFFECTIVENESS OF TIROFIBAN IN ACUTE CORONARY SYNDROME

 

Lee YC1, Mueller A2, Ryder S3, Kleijnen J1, Armstrong N1
1Kleijnen Systematic Reviews Ltd., York, UK, 2Analytic Services, Munchen, Germany, 3Kleijnen Systematic Reviews Ltd., YorK, UK

PRM75

PARALLEL SETS AS INTERACTIVE VISUALIZATION APPROACH FOR ANALYZING MARKOV MODELS

 

Urach C1, Piringer H2, Popper N3, Breitenecker F1
1Vienna University of Technology, Vienna, Austria, 2VRVis Zentrum für Virtual Reality und Visualisierung Forschungs-GmbH, Vienna, Austria, 3Dwh Simulation Services, Vienna, Austria

PRM76

A TREATMENT SEQUENCE APPROACH FOR MODELLING CROHN'S DISEASE

 

Lee D1, Gladwell D1, Batty A1, Berry P2, Smith HT3
1BresMed, Sheffield, UK, 2GSK, King of Prussia, PA, USA, 3GSK, Brentford, UK

PRM77

MAPPING THE MEANINGS OF WORDS PATIENTS USE TO DESCRIBE THEIR PAIN

 

Scanlon M1, Martin ML2, McCarrier KP2, Wolfe M1, Bushnell DM1
1Health Research Associates, Inc., Mountlake Terrace, WA, USA, 2Health Research Associates, Inc., Seattle, WA, USA

PRM78

MAPPING OF THE NATIONAL EYE INSTITUTE 25-ITEM VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25) TO EQ-5D UTILITY SCORES

 

Kay S1, Ferreira A2
1Adelphi Real World, Bollington, UK, 2Novartis Pharma AG, Basel, Switzerland

PRM79

INTEGRATING PATIENT PREFERENCES AND CLINICAL TRIAL DATA IN A BAYESIAN MODEL FOR QUANTITATIVE RISK-BENEFIT ASSESSMENT

 

Broekhuizen H1, IJzerman MJ1, Groothuis-Oudshoorn KG1, Hauber AB2
1University of Twente, Enschede, The Netherlands, 2RTI Health Solutions, Research Triangle Park, NC, USA

PRM80

PROPORTIONAL HAZARDS ASSUMPTION AND ITS IMPACT ON RESULTS OF COST-EFFECTIVENESS ANALYSIS

 

Pochopien M, Zerda I, Gwiosda B, Plisko R
HTA Consulting, Krakow, Poland

PRM81

METHODS OF OBTAINING EVIDENCE FROM PUBLISHED SURVIVAL DATA FOR USE IN DECISION ANALYTIC MODELS

 

Trueman D, Livings C, Mildred M
Abacus International, Bicester, Oxfordshire, UK

PRM82

VERIFICATION OF PROPORTIONAL HAZARDS ASSUMPTION IN COST-EFFECTIVENESS ANALYSIS (CEA)

 

Zerda I, Gwiosda B, Plisko R
HTA Consulting, Krakow, Poland

PRM83

COMPARING METHODS OF MIXED TREATMENT COMPARISONS IN HEALTH ECONOMIC MODELS

 

Vemer P1, Al MJ2, Oppe M1, Rutten-van Mölken MP2
1iMTA, Rotterdam, The Netherlands, 2Erasmus University, Rotterdam, The Netherlands

PRM84

USING PROPORTIONAL HAZARD MODELS TO PREDICT PRICE CHANGES OF ONCOLOGY DRUGS IN THE UNITED STATES

 

Wang BCM1, Tsang KP2, Patel P3
1Adjility Health, New York, NY, USA, 2Virginia Tech, Blacksburg, VA, USA, 3Adjility Health, London, UK

PRM85

INTERNAL VALIDATION OF THE SYREON DIABETES MODEL

 

Merész G1, Nagyjanosi L1, Nagy B2, Dessewffy Z3, Vokó Z4, Kalo Z5
1Syreon Research Institute, Budapest, Hungary, 2ELTE, Budapest, Hungary, 3Novartis Hungary, Budapest, Hungary, 4Eötvös Loránd University, Budapest, Hungary, 5Eötvös Loránd University, Budapest, Hungary

PRM86

UTILIZING INDIRECT TREATMENT COMPARISONS IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)

 

Wasiak R1, Joulain F2, Lambrelli D1, Trask PC3, Sartor O4
1United BioSource Corporation, London, UK, 2Sanofi-Aventis, Massy, France, 3Sanofi, Cambridge, MA, USA, 4Tulane University, New Orleans, LA, USA

RESEARCH ON METHODS – Patient-Reported Outcomes Studies

PRM87

CROSS-CULTURAL VALIDATION OF THE HUNTINGTON QUALITY OF LIFE INSTRUMENT IN SPAIN

 

Khemiri A1, Clay E2, Trigo P3, Yebenes J3, Toumi M4
1Creativ-Ceutical, Tunis, Tunisia, 2Creativ-Ceutical, Paris, France, 3Hospital Ramón y Cajal, Madrid, Spain, 4University Claude Bernard Lyon 1, Lyon, France

PRM88

TRANSLATION AND VALIDATION OF OSTEOPOROSIS HEALTH BELIEF SCALE INTO MALAYSIAN VERSION AMONG TYPE 2 DIABETICS PATIENTS

 

Abdulameer SA1, Syed Sulaiman SA1, Hassali MA1, Subramaniam K2, Sahib MN1
1Universiti Sains Malaysia, Minden, Penang, Malaysia, 2Penang General Hospital, George Town, Penang, Malaysia

PRM89

STANDARDIZING THE METRIC AND INCREASING THE EFFICIENCY OF PHYSICAL FUNCTIONING OUTCOMES MEASUREMENT

 

Ware J1, Guyer R2, Harrington M2, Boulanger R2
1University of Massachusetts Medical School, Worcester, MA, USA, 2John Ware Research Group, Worcester, MA, USA

PRM90

OUTCOME DIFFERENCES IN ALGORITHMS USED FOR INDIRECT MAPPING OF UTILITY VALUES FROM HAQ-DI: AN ASSESSMENT BASED ON PHASE 2A CLINICAL TRIAL DATA IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER TREATMENT WITH NNC0109-0012 (ANTI-IL-20 MAB)

 

Strandberg-Larsen M1, Hansen BB1, Göthberg M1, Valencia X2
1Novo Nordisk A/S, Søborg, Denmark, 2Novo Nordisk Inc, Princeton, NJ, USA

PRM91

HOW DO PATIENTS WITH DIFFERENT CONDITIONS DESCRIBE THEIR PAIN?

 

Martin ML1, Scanlon M2, McCarrier KP1, Wolfe M2, Bushnell DM2
1Health Research Associates, Inc., Seattle, WA, USA, 2Health Research Associates, Inc., Mountlake Terrace, WA, USA

PRM92

EXPLORATORY MAPPING OF THE LUPUSQOL TO THE SF-6D

 

Meacock R1, Harrison M1, McElhone K2, Isenberg D3, Ferenkeh-Koroma A4, Ahmad Y5, Bruce IN1, Shelmerdine J6, Gordon C7, Griffiths B8, Maddison P9, Akil M10, Abbott J11, Teh LS2
1University of Manchester, Manchester, UK, 2Royal Blackburn Hospital, Blackburn, UK, 3University College London Hospitals, London, UK, 4University College London, London, UK, 5Betsi Cadwaldr University Health Board, Llandudno, UK, 6Macclesfield District General Hospital, Macclesfield, UK, 7University of Birmingham, Birmingham, UK, 8Freeman Hospital, Newcastle, UK, 9Bangor University, Bangor, UK, 10Royal Hallamshire Hospital, Sheffield, UK, 11University of Central Lancashire, Preston, UK

PRM93

INFANTILE HEMANGIOMA ON FAMILIES,CREATION OF A SPECIFIC BURDEN QUESTIONNAIRE

 

Boccara O1, Meni C1, Labreze C2, Bodemer C3, Voisard JJ4, Taieb C5
1Necker Hospital, Paris, France, 2Hospital Pellegrin, Bordeaux, France, 3René Descartes University, Paris, France, 4PFD, Lavaur, France, 5CREES PFSA, Boulogne , France

PRM94

A NEW STEP IN THE USE OF COMPUTER ADAPTIVE TESTS FOR MEASURING QUALITY OF LIFE. CULTURAL ADAPTATION AND CALIBRATION IN SPAIN OF TWO PROMIS ITEM BANKS: PAIN-BEHAVIOUR AND PAIN-INTERFERENCE

 

Castejón N1, Rodríguez A1, Correia H2, Choi S2, Gálvez R3, Mayoral V4, Rebollo P5
1LA-SER (BAP LA-SER Outcomes), Oviedo, Spain, 2The PROMIS Statistical Center Northwestern University, Chicago, IL, USA, 3Hospital Virgen de las Nieves, Granada, Spain, 4Hospital de Bellvitge, Barcelona, Spain, 5LA-SER (BAP LA-SER Outcomes), Oviedo, Asturias, Spain

PRM95

DOES THE CAT QUESTIONNAIRE PRODUCE SIMILAR RESULTS WHEN SELF- OR INTERVIEWER-ADMINISTERED?

 

Badia X1, Agusti A2, Soler JJ3, Molina J4, Cenoz S5, Roset M6, Garcia-Losa M7
1IMS Health, Barcelona, Barcelona, Spain, 2Hospital Clínic IDIBAPS, Barcelona & CIBER Enfermedades Respiratorias (Spain), Barcelona, Spain, 3Hospital de Requena, Requena (Valencia), Spain, 4Centro de Salud Francia, Madrid, Spain, 5GlaxoSmithKline, Tres Cantos, Madrid, Spain, 6IMS Health, Barcelona, Spain, 7IMS Health, Madrid, Spain

PRM96

RELIABILITY OF A PATIENT-REPORTED ADVERSE DRUG EVENT QUESTIONNAIRE

 

de Vries ST, de Zeeuw D, Haaijer-Ruskamp FM, Denig P
University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

PRM97

TRANSLATION AND VALIDATION OF OSTEOPOROSIS KNOWLEDGE TOOL INTO MALAYSIAN VERSION AMONG TYPE 2 DIABETICS PATIENTS

 

Abdulameer SA1, Syed Sulaiman SA1, Hassali MA1, Subramaniam K2, Sahib MN1
1Universiti Sains Malaysia, Minden, Penang, Malaysia, 2Penang General Hospital, George Town, Penang, Malaysia

PRM98

OPTIMIZING DISCRETE CHOICE EXPERIMENT DESIGNS USING SIMULATIONS

 

Tapager IW, Jensen HH, Mønsted C, Bøgelund M
Incentive Partners, Holte, Denmark

PRM99

TRANSLATION AND VALIDATION OF OSTEOPOROSIS SELF-EFFICACY SCALE INTO MALAYSIAN VERSION AMONG TYPE 2 DIABETICS PATIENTS

 

Abdulameer SA1, Syed Sulaiman SA1, Hassali MA1, Subramaniam K2, Sahib MN1
1Universiti Sains Malaysia, Minden, Penang, Malaysia, 2Penang General Hospital, George Town, Penang, Malaysia

PRM100

CONVERTING EORTC QOL-C30 SCORES TO UTILITY VALUES: IS IT PLAUSIBLE?

 

Salek MS1, Schmidt-Rimpler C2, Wimberger P3, Gilet H4, Parsons SL5
1Cardiff University, Cardiff, UK, 2Fresenius Biotech GmbH, München, Germany, 3University of Duisburg-Essen, Essen, Germany, 4MAPI Consultancy, Lyon, France, 5Notthingham University Hospitals NHS Trust, Nottingham, UK

PRM101

A THINK ALOUD STUDY COMPARING THE VALIDITY AND ACCEPTABILITY OF DISCRETE CHOICE AND BEST WORST SCALING METHODS

 

Whitty JA1, Walker R2, Golenko X1, Ratcliffe J3
1Griffith University, Meadowbrook, Queensland, Australia, 2Flinders University, Adelaide, South Australia, Australia, 3Flinders University, Daw Park, South Australia, Australia

PRM102

VALIDATION OF THE RUSSIAN VERSION OF SCHIZOPHRENIA QUALITY OF LIFE QUESTIONNAIRE (S-QOL)

 

Millier A1, Khemiri A2, Clay E1, Antonova S3, Auquier P4, Aballea S1, Toumi M5
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, Tunis, Tunisia, 3CRO BioMed, Moscow, Russia, 4Timone University Hospital, Marseille, France, 5University Claude Bernard Lyon 1, Lyon, France

PRM103

ESTIMATING HEALTH RELATED QUALITY IN TYPE 2 DIABETIC PATIENTS RECEIVING POLYTHERAPY WITH EQ5D-5L QUESTIONNAIRE

 

Gorostiza I1, Echeto A2, Escobar A3, Acevedo P4, Gardeazabal MJ5
1Basurto University Hospital (Osakidetza), Bilbao, Spain, 2Basque Government - Gobierno Vasco, Vitoria - Gasteiz, Spain, 3Basurto University Hospital (Osakidetza), Bilbao, Bizkaia, Spain, 4Gobierno Vasco - Basque Government, Vitoria-Gasteiz, Spain, 5Gobierno Vasco - Basque Government, Vitoria - Gasteiz, Spain

PRM104

EXAMINATION OF PATIENT PREFERENCE: COMPARISONS OF RESULTS FROM THE TIME TRADE-OFF AND STANDARD GAMBLE INSTRUMENTS

 

Iskedjian M1, Navarro V2, Farah B1, Berbari J1, LeLorier J3
1PharmIdeas Research and Consulting, Ottawa, ON, Canada, 2PharmIdeas Europe SAS, Lyon, France, 3Université de Montréal, Montréal, QC, Canada

PRM105

PREDICTING SUBJECTIVE ANTIMUSCARINIC EFFECTIVENESS ON SYMPTOMS OF OVERACTIVE BLADDER USING THE EIGHT-ITEM OVERACTIVE BLADDER AWARENESS TOOL (OAB-V8)

 

Villacampa-Aubá F1, Ruiz MA2, Errando-Smet C3, Arlandis-Guzmán S4, Arumi D5, Lizarraga I6, Rejas J7
1Department of Urology, Hospital 12 de Octubre, Madrid, Spain, 2Universidad Autonoma de Madrid, Madrid, Spain, 3Department of Urology, Fundación Puigvert, Barcelona, Spain, 4Hospital Universitario La Fe, Valencia, Comunidad Valenc, Spain, 5Pfizer Inc., Madrid, Spain, Alcobendas, Madrid, Spain, 6Medical Unit, Pfizer España, Alcobendas, Madrid, Spain, 7Pfizer España, Alcobendas/Madrid, Spain

PRM106

EXAMINATION OF PREFERENCES ELICITED FROM THE GENERAL PUBLIC: COMPARISONS OF RESULTS FROM THE TIME TRADE-OFF AND STANDARD GAMBLE INSTRUMENTS

 

Iskedjian M1, Navarro V2, Farah B1, Berbari J1, Walker JH3, LeLorier J4
1PharmIdeas Research and Consulting, Ottawa, ON, Canada, 2PharmIdeas Europe SAS, Lyon, France, 3Brock University, St Catharines, ON, Canada, 4Université de Montréal, Montréal, QC, Canada

PRM107

NONPROBABILITY VERSUS PROBABILITY-BASED PATIENT SAMPLING: UNDERSTANDING RESPONSE VARIATION AND IMPLICATIONS

 

Sulham K1, Peugh J2, Edge J3, DiSogra CA4, Garfield S1
1GfK Bridgehead, Wayland, MA, USA, 2GfK Government & Academic Research, New York, NY, USA, 3Consumer Experiences GfK Custom Research, LLC, Chicago, IL, USA, 4GfK Sampling Statistics, Palo Alto, CA, USA

PRM108

RELIABILITY, VALIDITY, AND ABILITY TO DETECT CHANGE OF THE FACT-AN FOR USE IN PATIENTS WITH ANAEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE

 

Wiklund I1, Jin Y2, Chen WH2, van Nooten F3, Garcia-Hernandez A4, Holmstrom S4
1United BioSource Corporation, London, UK, 2United BioSource Corporation, Bethesda, MD, USA, 3Astellas Pharma Europe B.V., Leiderdorp, The Netherlands, 4Astellas Pharma Global Development, Leiderdorp, The Netherlands

PRM109

CONTENT VALIDITY OF A TREATMENT SATISFACTION QUESTIONNAIRE IN NON-HODGKIN'S LYMPHOMA

 

Campbell A1, Wiesner C2, Garcia EB2, Tatlock S3, Humphrey L4
1Genentech, South San Francisco, CA, USA, 2F. Hoffmann-La Roche Ltd., Basel, Switzerland, 3Adelphi Values, Bollington, Cheshire, UK, 4Adelphi Values, Cheshire, UK

PRM110

WITHDRAWN

 

 

PRM111

PEDIATRIC PATIENT-REPORTED OUTCOMES ASSESSMENT: A CASE STUDY IN EPIDERMOLYSIS BULLOSA

 

Mordin M1, Clark M1, Doward L2, Willian MK3
1RTI Health Solutions, Ann Arbor, MI, USA, 2RTI Health Solutions, Manchester, Manchester, UK, 3Advanced BioHealing, A Shire Company, La Jolla, CA, USA

PRM112

RECRUITMENT COSTS AND EFFICIENCY VARIES WITH CONDITION/ PATIENT POPULATION

 

Pumford N, Wade A, Crawford G
Patients Direct, Glasgow, UK

PRM113

DEVELOPMENT OF A GENERIC SPANISH VERSION OF THE MODIFIED MYELOFIBROSIS SYMPTOM ASSESSMENT FORM (MFSAF) DIARY

 

Boucher F1, Joulain F2, Mesa R3, Emanuel R4
1MAPI Institute, Lyon, France, 2Sanofi-Aventis, Massy, France, 3Mayo Clinic, Scottsdale , AZ, USA, 4Mayo Clinic, Scottsdale, AZ, USA

PRM114

THE CHALLENGE OF TRANSLATING THE PICTURE NAMING SUBTEST OF THE REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS (RBANS)

 

Rendu E1, Harel B2, Nomikos A2, Caveney A3, Acquadro C4, Anfray C1
1MAPI Institute, Lyon, France, 2CogState, New Haven, CT, USA, 3University of Michigan, Ann Arbor, MI, USA, 4MAPI Research Trust, Lyon, France

PRM115

MODELLING THE RELATIONSHIP BETWEEN DISEASE SEVERITY AND UTILITY IN MULTIPLE SCLEROSIS

 

Fogarty E1, Walsh C2, Grehan S2, Schmitz S3, McGuigan C4, Tubridy N4, Barry M5
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2Trinity College Dublin, Dublin, Ireland, 3Trinity College Dublin, Dublin, Dublin, Ireland, 4St. Vincent's University Hospital, Dublin, Ireland, 5St. James's Hospital, Dublin, Ireland, Ireland

PRM116

PAYER AND PATIENT PERCEPTIONS OF MEDICATION VALUE AND THE ROLE OF PATIENT-REPORTED OUTCOMES

 

Cascade E1, Andreykiv M2, Istas A3
1Quintiles, Rockville, MD, USA, 2Quintiles, Hoofddorp, The Netherlands, 3Quintiles, Oak Park, IL, USA

PRM117

EXPLORING PATIENT PERCEPTIONS OF, AND PREFERENCES FOR, PAIN RESPONSE SCALES

 

Quadri N1, Langel K2, Muehlhausen W1, O'Donohoe P3, Wild D1
1Oxford Outcomes, An ICON plc Company, Oxford, UK, 2CRF Health, Helsinki, Finland, 3CRF Health, London, UK

PRM118

METHODOLOGY FOR NEUROPSYCHOLOGICAL ASSESSMENT WORDLIST ADAPTATION

 

Simon M1, Zarzar K2, Settar C3
1TransPerfect, Paris, France, 2TransPerfect, Research Triangle Park, NC, USA, 3TransPerfect, New York, NY, USA

PRM119

MAPPING BETWEEN COMPOSITE MEASURES IN PSORIATIC ARTHRITIS AND THE SF-6D: ANALYSIS FROM THE GRACE DATASET

 

Adams RC1, Walsh C2, Barry M3, Fitzgerald O4, Helliwell P5
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2Trinity College Dublin, Dublin, Ireland, 3St. James's Hospital, Dublin, Ireland, Ireland, 4St. Vincents University Hospital, Dublin Academic Healthcare, Dublin, Ireland, 5University of Leeds, Leeds, UK

PRM120

PATHWAYS TO EFFECTIVE CLINRO DOSSIER DEVELOPMENT

 

Bennett BM1, Ballinger R1, Nixon A2
1Oxford Outcomes, Oxford, UK, 2Oxford Outcomes, Oxford , UK

PRM121

BURDEN OF OSTEOARTHRITIS :DEVELOPMENT OF A QUESTIONNAIRE

 

Bertin P1, Coudert T2, Rannou F3, Grange L4, Taieb C5
1Comité LUtte contre la Douleur, Limoges, France, 2PFSA, Boulogne Billancourt, France, 3Hopital Cochin,, Paris, France, 4CHU Grenoble, Grenoble, France, 5CREES PFSA, Boulogne , France

PRM122

ATOPIC DERMATITIS ON FAMILIES: CREATION OF A SPECIFIC BURDEN QUESTIONNAIRE

 

Meni C1, Bodemer C2, Toulon A1, Branchoux S3, Taieb C4
1Necker Hospital, Paris, France, 2René Descartes University, Paris, France, 3Pierre Fabre, Boulogne Billancourt, France, 4CREES PFSA, Boulogne , France

PRM123

WITHDRAWN

 

PRM124

TRANSLATION OF THE ALCOHOL TIMELINE FOLLOWBACK (TLFB) IN 4 LANGUAGES

 

Trevin A1, Carter Sobell L2, Sobell M2
1MAPI Institute, Lyon, France, 2Center for Psychological Studies, Nova Southeastern University, Fort Lauderdale, FL, USA

PRM125

WHOSE VALUES IN HEALTH? A COMPARISON OF ADULT AND ADOLESCENT VALUES FOR THE CHU9D AND AQOL-6D

 

Ratcliffe J
Flinders University, Daw Park, South Australia, Australia

PRM126

CHOICE-BASED VALUATION OF THE SF-12V1

 

Craig BM1, Watson V2, Busschbach JJV3
1Moffitt Cancer Center, Tampa, FL, USA, 2University of Aberdeen, Aberdeen, UK, 3Erasmus University Medical Center, Rotterdam, The Netherlands

PRM127

MEASURING QUALITY OF LIFE IN MENTAL HEALTH: ISSUES AND CHALLENGES

 

Lewis L, Taylor M, Roberts S
University of York, York, UK

PRM128

DEVELOPMENT OF A TRANSLATION EVIDENCE TRACKING TOOL TO COMPLY WITH THE FDA REVIEW REQUIREMENTS FOR THE TRANSLATION OF PRO INSTRUMENTS

 

Mear I1, Anfray C1, Conway K2
1MAPI Institute, Lyon, France, 2MAPI Research Trust, Lyon, France

PRM129

FINAL REPORTS FOR TRANSLATION AND LINGUISTIC VALIDATION OF CLINICAL OUTCOME ASSESSMENTS

 

Zarzar K1, Chulis C2, Simon M3
1TransPerfect, Research Triangle Park, NC, USA, 2TransPerfect, New York, NY, USA, 3TransPerfect, Paris , France

PRM130

TRANSLATABILITY OF RESPONSE SETS USED IN PATIENT REPORTED OUTCOMES AND BEST PRACTICES FOR DEVELOPMENT

 

Gawlicki MC1, McKown S2, Talbert M2, Brandt BA1
1Corporate Translations, Inc., East Hartford, CT, USA, 2Corporate Translations, Inc., Chicago, IL, USA

PRM131

HOW MIGHT EXPERIENCE-BASED UTILITY MEASURES INFLUENCE REIMBURSEMENT DECISIONS?

 

Marsh K, Browne C
United BioSource Corporation, London, UK

PRM132

USING CLINICAL OUTCOME ASSESSMENTS AND ECONOMIC DATA TO FACILITATE PATIENT ACCESS IN RHEUMATOID ARTHRITIS

 

Gater A1, Kitchen H1, Heron L1, Hansen BB2, Højbjerre L2, Strandberg-Larsen M2
1Adelphi Values, Bollington, Cheshire, UK, 2Novo Nordisk A/S, Søborg, Denmark

PRM133

REVIEWING TRANSLATABILITY PRIOR TO TRANSLATION AND LINGUISTIC VALIDATION OF PROS

 

Anderson H1, Gordon-Stables R2, Wild D3
1Oxford Outcomes, An ICON plc Company, Oxford , UK, 2Oxford Outcomes Ltd., Oxford, Oxon, UK, 3Oxford Outcomes, An ICON plc Company, Oxford, Oxon, UK

PRM134

REGRESSION METHODS FOR HEALTH-RELATED QUALITY OF LIFE DATA IN LONGITUDINAL SETTINGS: ARE MORE ADVANCED TECHNIQUES REALLY PERFORMING BETTER?

 

Hunger M, Döring A, Holle R
Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Neuherberg, Germany

PRM135

VALIDITY, RELIABILITY AND RESPONSIVENESS OF THE SPANISH MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE

 

Bilbao A1, Escobar A1, Fernandez-Soto ML2, Gonzalez-Saenz de Tejada M3, Lafuente I4
1Basurto University Hospital (Osakidetza), Bilbao, Bizkaia, Spain, 2Donostia University Hospital (Osakidetza), Donostia-San Sebastian, Gipuzkoa, Spain, 3Basurto University Hospital (Osakidetza) - CIBER Epidemiologia y Salud Pública (CIBERESP), Bilbao, Bizkaia, Spain, 4Galdakao-Usansolo Hospital (Osakidetza), Galdakao, Bizkaia, Spain

PRM136

A UTILITY SINGLE SCORE DERIVED FROM SHORT FORM-36 AND HEALTH ASSESSMENT QUESTIONNAIRE IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODY SYNDROME: A METHODOLODICAL PROPOSAL

 

Abreu MM1, Domingues V2, Signorelli F3, Ennes S4, Levy RA5
1Universidade Federal de São Carlos, São Carlos, São Paulo, Brazil, 2New York Presbyterian Hospital/Weill Cornell Medical College, new york, NY, USA, 3Hospital Universitário Pedro Ernesto, Rio de Janeiro, São Carlos, Brazil, 4Fernandes Figueira Institute, Rio de Janeiro, Brazil, 5Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil

PRM137

REMINDERS HELP IMPROVING COMPLETION RATE OF HOME-ADMINISTERED LIFESTYLE QUESTIONNAIRES

 

Wiederkehr S, Seux M, Faure C, Fournie X
Registrat-Mapi, LYON, France

RESEARCH ON METHODS – Statistical Methods

PRM138

A PROPENSITY TO GET IT RIGHT. A MONTE CARLO SIMULATION STUDY COMPARING STATISTICAL METHODS TO OBTAIN CORRECT COST-EFFECTIVENESS ESTIMATES IN OBSERVATIONAL STUDIES

 

van Gils CWM1, Goossens LMA2, Redekop WK3
1Erasmus University, Rotterdam - GlaxoSmithKline, Zeist, The Netherlands, 2Erasmus University, Rotterdam, The Netherlands, 3Erasmus University Rotterdam, Rotterdam, The Netherlands

PRM139

INCLUDING PATIENTS IN MULTIPLE GROUPS AND MULTIPLE TIMES IN THE SAME GROUP IN LONGITUDINAL OBSERVATIONAL RESEARCH: A CYSTIC FIBROSIS EXAMPLE

 

Pasta DJ, Millar SJ
ICON Late Phase & Outcomes Research, San Francisco, CA, USA

PRM140

AN APPLIED COMPARISON OF META-ANALYSIS TECHNIQUES USING BACILLE CALMETTE GUERIN VACCINE STUDIES

 

Lewis-Beck C1, Baser E2, Baser O3
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, Istanbul, MI, Turkey, 3STATinMED Research/The University of Michigan, Ann Arbor, MI, USA

PRM141

COMBINING AN ORDERED LOGIT MODEL WITH INDIVIDUAL PATIENT-LEVEL DATA TO ROBUSTLY ESTIMATE WITHIN-CATEGORY VISUAL ACUITY STARTING DISTRIBUTIONS: AN INNOVATIVE MODELING APPROACH IN THE CASE OF VITREOMACULAR TRACTION

 

Bennison C1, Thurston S2, Lescrauwaet B3, Bojakowski S4, Kozma-Wiebe P4
1Pharmerit International, York, UK, 2Pharmerit Ltd, York, UK, 3Xintera Consulting, Leuven, Belgium, 4ThromboGenics NV, Heverlee, Belgium

PRM142

USE OF BODY SURFACE AREA AS A DETERMINANT OF DOSE IN CANCER STUDIES

 

Trappe RU1, Cooke C2, Heatley R2, Johnson KI2, Wiesner C3
1Universitätsklinikum Schleswig-Holstein, Kiel, Germany, 2Complete Clarity, Macclesfield, Cheshire, UK, 3F. Hoffmann-La Roche Ltd., Basel, Switzerland

PRM143

CLUSTER ANALYSIS AND PRINCIPAL COMPONENT ANALYSIS TO ASSESS THE VARIABILITY OF DATA IN COST EVALUATIONS: METHODS AND APPLICATIONS IN ONCOLOGY

 

Perrier L1, Buja A2, Mastrangelo G2, Sylvestre Baron P3, Pauwels P4, Ricardo Rossi C5, Gilly FN6, Ducimetière F1, Favier B1, Farsi F7, Laramas M8, De Marliave H9, Collard O10, Cellier D11, Blay JY1, Ray Coquard I1
1Leon Berard Cancer Centre, Lyon, France, 2University of Padova, Padova, Veneto, Italy, 3University Lyon 2, Lyon, France, 4CLARA, Lyon, France, 5University of Padova, Padova, Italy, 6University Hospital Lyon Sud, Pierre Bénite, France, 7Réseau Espace Santé Cancer, Lyon, France, 8University hospital of Grenoble, La Tronche, France, 9Clinique Belledonne, Saint Martin d'Hères, France, 10Institut de Cancérologie de la Loire, Saint Priest en Jarez , France, 11Merck Santé, Lyon, France

PRM144

CARDIOLOGISTS' KNOWLEDGE AND AWARENESS OF GUIDELINES FOR MEDICAL DEVICE SAFETY AND PRODUCT RISK MANAGEMENT

 

Bozkurt R1, Yildirim J2
1Turkish Social Security Institution, Ankara, Turkey, 2TED UNIVERSITY, ANKARA, Turkey

PRM145

A MAXIMUM LIKELIHOOD SIMULATION TECHNIQUE FOR ESTIMATING ADVERSE EVENT RATES FROM PUBLISHED TRIALS

 

Wielage RC1, Samsa GP2, Klein TM1, Happich M3
1Medical Decision Modeling Inc., Indianapolis, IN, USA, 2Duke University, Durham, NC, USA, 3Lilly Deutschland GmbH, Bad Homburg, Hessen, Germany

PRM146

AN EXCEL CALCULATOR TOOL TO PERFORM META-ANALYSIS

 

Baser E1, Lewis-Beck C2, Baser O3
1STATinMED Research, Istanbul, MI, Turkey, 2STATinMED Research, Ann Arbor, MI, USA, 3STATinMED Research/The University of Michigan, Ann Arbor, MI, USA

PRM147

COMPARISON OF INDIRECT AND MIXED TREATMENT COMPARISON (MTC) META-ANALYSIS TECHNIQUES USED IN THE EVALUATION OF NEW PROTEASE INHIBITORS FOR THE TREATMENT OF CHRONIC HEPATITIS C

 

Lion M1, Humphreys S1, Mills E2, O'Regan C3
1MSD Ltd., Hoddesdon, UK, 2University of Ottawa, Ottawa, ON, Canada, 3Merck Sharp & Dohme Ltd., Hoddesdon, UK

PRM148

SAMPLE SIZE AND POWER CONSIDERATIONS IN NETWORK META-ANALYSIS

 

Thorlund K1, Mills E2
1McMaster University, Hamilton, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada

PRM149

A RANDOM UTLITY MODEL USING A TRANSACTION COST POLITICS APPROACH TO ADJUST HEALTH SYSTEMS TO ECONOMIC TRANSITION

 

Huttin Christine C
ENDEPUSresearch and endepresearch group , University Aix Marseille, Cambridge, MA, USA

PRM150

LATENT TRANSITION ANALYSIS AS A TOOL FOR ANALYSING CLINICAL DATA

 

Mayer D1, Burgess AJ2
1Quintiles, Reading, Berkshire, UK, 2Quintiles/Outcome, Rearding, Berkshire, UK

PRM151

COLLAPSIBILITY AND CENSORING: WHAT'S THE BIAS IN ESTIMATED SURVIVAL TIME?

 

Goossens LMA1, van Gils CWM2, Redekop WK3
1Erasmus University, Rotterdam, The Netherlands, 2Erasmus University, Rotterdam - GlaxoSmithKline, Zeist, The Netherlands, 3Erasmus University Rotterdam, Rotterdam, The Netherlands

RESEARCH ON METHODS – Study Design

PRM152

IS IT JUST SEMANTICS? THE USE OF “EFFICACY” AND “EFFECTIVENESS” IN COMPARATIVE EFFECTIVENESS REVIEWS AND HEALTH TECHNOLOGY ASSESSMENTS

 

Jaksa A, Rubinstein E, Ho YS, Daniel K
Context Matters, Inc., New York, NY, USA

PRM153

PRIORITIZING MULTIPLE PATIENT-RELEVANT ENDPOINTS - A METHODOLOGICAL COMPARISON OF CONJOINT ANALYSIS AND ANALYTIC HIERARCHY PROCESS CONSIDERING IQWIG`S EFFICIENCY FRONTIER CONCEPT

 

Neidhardt K1, Wasmuth T1, Schmid A2
1Novartis Pharma GmbH, Nürnberg, Germany, 2University of Bayreuth, Bayreuth, Germany

PRM154

SOURCE DATA VERIFICATION – A SURVEY OF CURRENT PRACTICE

 

Velthuis EJM1, Malka ES2, Richards MS2, Orr M2, Sernau T3
1PPD, Bennekom, The Netherlands, 2PPD, Morrisville, NC, USA, 3PPD, Karlsruhe, Germany

PRM155

A PRAGMATIC RANDOMIZED CLINICAL TRIALS – DESIGN AND QUALITY ASSESSMENT OF THE SOURCE OF EFFECTIVENESS DATA

 

Kaczynski L, Solnica B
Jagiellonian University Medical College, Cracow, Malopolska, Poland

PRM156

HOW TO INCREASE PATIENT RETENTION RATE DURING THEIR PARTICIPATION IN LONGITUDINAL STUDIES

 

El Kebir S1, Gauchoux R2, Nichols SE3
1Registrat-Mapi, Lexington, KY, USA, 2Registrat-Mapi, Lyon, France, 3Registrat-Mapi, Lexington , KY, USA

PRM157

METHODOLOGICAL CHALLENGES OF IQWIG'S EFFICIENCY FRONTIER CONCEPT ELICITED BY MULTIPLE PATIENT-RELEVANT ENDPOINTS – WHY PRIORITIZATION OF ENDPOINTS CANNOT BE AVOIDED

 

Neidhardt K, Wasmuth T
Novartis Pharma GmbH, Nürnberg, Germany

PRM158

PLACEBO-CONTROLLED CLINICAL TRIALS: A DIFFICULT BALANCE “JUSTIFICATION VERSUS FEASIBILITY” FOR ACADEMIC SPONSORS

 

Duracinsky M, Taron C, Matei M, Chassany O
Assistance Publique-Hopitaux de Paris, Paris, France

RESEARCH ON METHODS – Conceptual Papers

PRM159

SENSITIVITY ANALYSIS VERSUS UNCERTAINTY ANALYSIS IN HEALTH ECONOMIC DECISION MAKING

 

O'Day K1, Bramley T2
1Xcenda, Palm Harbor, FL, USA, 2Xcenda, LLC, Palm Harbor, FL, USA

PRM160

A NEW VALUE-BASED PRICING FRAMEWORK FOR THE OPTIMAL PRICING OF PHARMACEUTICAL ASSETS

 

Hawryluk EA, Malhotra M, Chawla V, Doyle J
Quintiles Global Consulting, Hawthorne, NY, USA

PRM161

A PARADIGM SHIFT IN HEALTH ECONOMIC EVALUATIONS FOR DEVELOPING COUNTRIES - OPTIMIZATION MODELLING FOR ASSESSING WHICH MIX OF MALARIA PREVENTION STRATEGIES ACHIEVES A DEFINED PUBLIC HEALTH TARGET AT THE LOWEST BUDGET

 

Van Vlaenderen I1, Sauboin C2, Van Bellinghen LA1, Standaert B2
1CHESS, Ternat, Belgium, 2GlaxoSmithKline Vaccines, Wavre, Belgium

PRM162

APPROPRIATE COMPARATIVE TREATMENTS FOR EARLY BENEFIT ASSESSMENT (EBA) IN GERMANY. COMPARING THE SUGGESTIONS BY THE JOINT FEDERAL COMMITTEE (GBA) AND THE PHARMACEUTICAL COMPANIES

 

Ruof J1, Scherer J1, Schulenburg JM2
1Roche Pharma, Grenzach-Wyhlen, Germany, 2Leibniz University Hannover, Hannover, Germany

PRM163

THE USE OF EXPECTED VALUE OF PERFECT INFORMATION ANALYSIS WITHIN ECONOMIC EVALUATIONS AND HEALTH TECHNOLOGY ASSESSMENTS IN THE UNITED KINGDOM

 

Almond C1, Brereton NJ2
1BresMed Health Solutions, Sheffield, South Yorkshire, UK, 2BresMed, Sheffield, UK

PRM164

ENSURING THE VALUE OF A MEDICAL DEVICE INNOVATION PRIOR TO MARKET LAUNCH

 

Hidefjall P
KTH Royal School of Technology, Huddinge, Sweden

PRM165

VALIDATING HEALTH ECONOMIC MODELS: DEVELOPING A METHODOLOGICAL APPROACH

 

Hart WM1, Chandler F2
1EcoStat Consulting Ltd, Sidestrand, Norfolk, UK, 2GlaxoSmithKline, Uxbridge, Middlesex , UK

PRM166

THE CHALLENGE OF ASSESSING HEALTH TECHNOLOGIES EARLY IN THE DEVELOPMENT. SYSTEMATIC LITERATURE REVIEW OF METHODS IN USE

 

Markiewicz K, van Til J, IJzerman MJ
University of Twente, Enschede, The Netherlands

PRM167

THE VALUE OF CHOICE IN A COLLECTIVELY FUNDED HEALTH SYSTEM: AN EXTENDED ANALYTICAL APPROACH TO EXAMINE THE CONFLICT BETWEEN DECISIONS AT INDIVIDUAL AND SOCIETAL LEVEL

 

Espinoza MA
University of York, Heslington, York, UK

PRM168

AN INTEGRATED FORMAL FRAMEWORK FOR REIMBURSEMENT, RESEARCH AND PRICING DELIBERATIONS IN HEALTH TECHNOLOGY ASSESSMENT

 

Griffin S1, Spackman E2, Soares MO3, McKenna C3, Claxton K4
1University of York, York, North Yorkshire, UK, 2University of York, Heslington, North Yorkshire, UK, 3University of York, York, UK, 4University of York, Heslington, York, UK

PRM169

INTERNAL AND EXTERNAL VALIDITY IN ECONOMIC MODELING: CONSIDERATIONS BASED ON A PUBLISHED EXAMPLE

 

Porzsolt F
University of Ulm, Ulm, Germany

PRM170

OPTIMIZING PUBLIC HEALTH DECISION OVER TIME: A DYNAMIC BUDGET OPTIMIZATION MODEL WITH MULTIPLE CRITERIA DECISION MAKING

 

Ethgen O1, Topachevskyi O2, Connolly M3, Standaert B2
1University of Liege, Liege, Belgium, 2GlaxoSmithKline Vaccines, Wavre, Belgium, 3Global Market Access Solutions, St Prex, Switzerland

PRM171

OPTIMAL SHOPPING: AN EVAUATION OF DECISION RULES IN COST-EFFECTIVENESS ANALYSIS (CEA)

 

McKenna C1, Claxton K2
1University of York, York, UK, 2University of York, Heslington, York, UK

PRM172

THE VALUE OF PERSONALIZED MEDICINE: IT IS MORE ABOUT UNVEILING THE PERFORMANCE OF THE COMPANION DIAGNOSTIC

 

Ethgen O
University of Liege, Liege, Belgium

PRM173

ON THE PROBABILITY OF INTERTEMPORAL INDIFFERENCE

 

Parouty M1, Postma M2
1University of Groningen, Groningen, The Netherlands, 2Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen, Groningen , The Netherlands

PRM174

THE NEED TO CONDUCT FUTURE RESEARCH ON THE BENEFIT OF THE PROSTATE SPECIFIC ANTIGEN SCREENING TEST USING THE VALUE OF INFORMATION FRAMEWORK

 

Reese ES, Mullins CD
University of Maryland School of Pharmacy, Baltimore, MD, USA

PRM175

IDENTIFICATION AND TRANSLATION OF CULTURALLY BOUND TERMS IN PATIENT REPORTED OUTCOME MEASURES

 

Simpson H, Two R, Verjee-Lorenz A, Clayson D
PharmaQuest Ltd, Banbury, UK

PRM176

WITHDRAWN

 

 

PRM177

WHAT IS THE ROLE OF EARLY HEALTH TECHNOLOGY ASSESSMENT OF BIOMARKERS IN THE PRE-CLINICAL DEVELOPMENT PHASE? A REFLECTION ON LESSONS LEARNED WITH MULTIPLE MYELOMA

 

Gaultney JG1, Redekop WK1, Sonneveld P2, Uyl-de Groot CA1
1Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands, 2Erasmus Medical Center, Rotterdam, The Netherlands

PRM178

EXCEL TO MOBILE: THE METHOD FOR AUTOMATED MIGRATION OF EXCEL-BASED MARKOV MODELS TO MODERN SOFTWARE PLATFORMS

 

Kutepov G1, Settenvini M2
1Fraunhofer IESE, Kaiserslautern, Germany, 2Technische Universität Kaiserslautern, Kaiserslautern, Germany

SESSION IV – TUESDAY, 6 NOVEMBER
SET-UP: Tuesday, 6 November, 14:45 – 15:00
POSTER DISPLAY HOURS: Tuesday, 6 November,15:00-19:00
POSTER AUTHOR DISCUSSION HOUR: Tuesday, 6 November, 18:00 – 19:00
DISMANTLE: Tuesday, 6 November, 19:00

DIABETES/ENDOCRINE DISORDERS – Clinical Outcomes Studies

PDB1

REAL-WORLD INCIDENCE OF HYPOGLYCEMIA AND ASSOCIATED COSTS AMONG INSULIN GLARGINE-TREATED PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)

 

Xie L1, Wei W2, Pan C3, Baser O4
1STATinMED Research, Ann Arbor, MI, USA, 2Sanofi-Aventis U.S., Bridgewater, NJ, USA, 3PRO Unlimited, Boca Raton, FL, USA, 4STATinMED Research/The University of Michigan, Ann Arbor, MI, USA

PDB2

SYSTEMATIC LITERATURE REVIEW OF THE EFFICACY AND SAFETY OF METFORMIN EXTENDED RELEASE RELATIVE TO METFORMIN IMMEDIATE RELEASE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS

 

Aranda-Reneo I1, Villoro R2, Hidalgo A3, Donato BMK4, Juarez-Garcia A5
1Universidad de Castilla - La Mancha, Talavera de la Reina, Toledo, Spain, 2Weber, Economía y Salud, Majadahonda, Madrid, Spain, 3Weber, Economía y Salud, Madrid, Madrid, Spain, 4Bristol-Myers Squibb Company, Wallingford, CT, USA, 5Bristol-Myers Squibb Company, Mexico, DF, Mexico

PDB3

HOW DIFFERENT WERE THEY? A TREATMENT PATTERN ANALYSIS OF UNITED STATES PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INITIATING INJECTABLE THERAPY

 

Walker V1, Wei W2, Thayer S3, Brekke L1, Crown W4, Grabner M5, Raparla S5, Quimbo R5, Cziraky M5, Hu W2, Cuddihy R2
1OptumInsight, Eden Prairie, MN, USA, 2Sanofi-Aventis U.S., Bridgewater, NJ, USA, 3OptumInsight, San Francisco, CA, USA, 4OptumInsight, Waltham, MA, USA, 5HealthCore, Inc., Wilmington, DE, USA

PDB4

HBA1C REDUCTION ASSOCIATED WITH INITIAL VERSUS SEQUENTIAL COMBINATION THERAPY WITH PIOGLITAZONE (PIO) AND DIPEPTIDYL PEPTIDASE-4 INHIBITORS (DPP4I) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)

 

Bron M1, Chen K2, Ayyagari R2, Sharma H2, Wu EQ2
1Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA, 2Analysis Group, Inc., Boston, MA, USA

PDB5

REAL-WORLD TREATMENT PATTERNS AND OUTCOMES WHEN INITIATING ONCE-DAILY INJECTABLE PEN THERAPY WITH INSULIN GLARGINE OR LIRAGLUTIDE – AN ELECTRONIC MEDICAL RECORDS STUDY

 

Mersey J1, Wei W2, Meyers J3, Wang CC4, Dalal MR5, Bromberger LA1, Levin P6
1MODEL Clinical Research, Baltimore, MD, USA, 2Sanofi-Aventis U.S., Bridgewater, NJ, USA, 3RTI Health Solutions, Research Triangle Park, NC, USA, 4RTI Health Solutions, RTP, NC, USA, 5Sanofi-Aventis U.S., BRIDGEWATER, NJ, USA, 6Bay West Endocrinology Associates, Baltimore, MD, USA

PDB6

REAL-WORLD COMPARATIVE EFFECTIVENESS ANALYSIS OF PATIENTS INITIATING INJECTABLE TREATMENTS FOR TYPE 2 DIABETES MELLITUS (T2DM): PILOT DATA FROM THE INITIATOR STUDY

 

Grabner M1, Wei W2, Raparla S1, Quimbo RA1, Cziraky MJ1, Thayer SW3, Brekke L4, Buysman E4, Crown W5, Hu W2, Cuddihy R2
1HealthCore, Inc., Wilmington, DE, USA, 2Sanofi-Aventis U.S., Bridgewater, NJ, USA, 3OptumInsight, San Francisco, CA, USA, 4OptumInsight, Eden Prairie, MN, USA, 5OptumInsight, Waltham, MA, USA

PDB7

CLINICAL AND RESOURCE UTILIZATION OUTCOMES: ELDERLY TYPE 2 DIABETES PATIENTS INITIATING INSULIN PENS VERSUS VIALS

 

Eby E1, Frois C2, Guerin A3, Boggs JA1, Nyhuis A1, Swindle R1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Analysis Group, Ltee., Montreal, QC, Canada

PDB8

WEIGHT LOSS OF ≥3% OF BODY WEIGHT AFTER INITIATING NEW ANTI-DIABETIC THERAPY IS ASSOCIATED WITH GLYCEMIC CONTROL AT 6 MONTHS IN PATIENTS WITH TYPE 2 DIABETES

 

McAdam-Marx C1, Bellows BK1, Wygant GD2, Mukherjee J3, Unni S1, Ye X1, Iloeje UH3, Brixner D1
1University of Utah, Salt Lake City, UT, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3Bristol-Myers Squibb, Wallingford, CT, USA

PDB9

OUTCOME OF FIXED DOSE RADIOACTIVE IODINE FOR THE TREATMENT OF HYPERTHYROIDISM

 

Obidiya SO1, Ogunjobi K2, Eniojukan JF1
1Niger Delta University, YENAGOA, Bayelsa State, Nigeria, 2University College Hospital, Ibadan, Oyo, Nigeria

PDB10

EFFECTIVENESS OF VILDAGLIPTIN COMPARED TO SULFONYLUREAS IN TYPE 2 DIABETES PATIENTS IN GERMANY: RESULTS FROM A LARGE REAL-LIFE COHORT STUDY

 

Dworak M1, Gruenberger JB2, Bader G2
1Novartis Pharma GmbH, Nuremberg, Germany, 2Novartis Pharma AG, Basel, Switzerland

PDB11

A LARGE-SCALE LONGITUDINAL POPULATION-BASED STUDY OF RISK REDUCTION OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS ON BOLUS INSULIN ANALOGUES

 

Cammarota S1, Bruzzese D2, Catapano AL3, Citarella A1, De Luca L1, Manzoli L4, Masulli M5, Flacco ME4, Menditto E1, Mezzetti A4, Riegler S1, Putignano D6, Casula M3, Riccardi G5
1CIRFF, Federico II University, Naples, Italy, 2Federico II University Hospital School of Medicine, Naples, Italy, 3University of Milan, Milan, Italy, 4University , Chieti, Italy, 5University of Naples, Naples, Italy, 6CIRFF, Federico II University, naples, Italy

PDB12

HOW HYPOGLYCAEMIC EVENTS CAN INFLUENCE DIABETIC PATIENTS' WEIGHT AND AFFECT HBA1C CONTROL

 

Ansolabehere X, Grandfils N, Le Jeunne P, Morlet Vigier D
IMS Health, Puteaux, France

PDB13

INTERIM RESULTS OF THE POST-MARKETING SURVEY OF VILDAGLIPTIN IN FRANCE

 

Bringer J1, Attali C2, Simon D3, Eschwège E4, Kind B5, Quere S6, Dejager S6, Bouée S7, Detournay B8
1CHRU Montpellier, Montpellier, France, 2Cabinet Médical de Groupe, Epinay sous sénart, France, 3Hôpital de la Pitié, Paris, France, 4INSERM, Villejuif, France, 5Novartis, Rueil-Malmaison, France, 6Novartis Pharma, Rueil Malmaison, France, 7Cemka, Bourg La Reine, France, 8Cemka, Bourg la Reine, France

PDB14

CHARACTERISTICS OF THE ABORIGINAL PEOPLE WITH DIABETES IN THE SOUTH-WESTERN OF ONTARIO, CANADA

 

reza Nakhai-Pour H1, Tarride JE1, Blackhouse G2, Xie F1, O'Reilly D3, Goeree R1, Petrella RJ4
1McMaster University, Hamilton, ON, Canada, 2Programs for Assessment of Technology in Health (PATH) Research Institute, Hamilton, ON, Canada, 3PATH Research Institute, McMaster University, Hamilton, ON, Canada, 4Lawson Health Research Institute, London, ON, Canada

PDB15

PREVALENCE OF HYPERTENSION AND/OR OBESITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS THROUGHOUT THE WORLD: A SYSTEMATIC LITERATURE REVIEW

 

Colosia AD1, Palencia R2, Khan S1
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Boehringer Ingelheim GmbH, Ingelheim, Germany

PDB16

GEOGRAPHIC VARIATION TRENDS IN DIABETES MELLITUS PREVALENCE IN THE UNITED STATES VETERAN POPULATION

 

Xie L1, Wang L2, Huang A2, Li L2, Fritschel EK2, Baser O3
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, Dallas, TX, USA, 3STATinMED Research/The University of Michigan, Ann Arbor, MI, USA

PDB17

SYSTEMATIC REVIEW OF EARLY LIFE DETERMINANTS OF METABOLIC SYNDROME AND DIABETES MELLITUS IN BANGLADESH, INDIA AND PAKISTAN

 

Callejo D1, Cuervo J1, Rebollo P1, Diaz H1, Hitman G2, Hussain A3
1LA-SER (BAP LA-SER Outcomes), Oviedo, Asturias, Spain, 2Queen Mary University of London, London, UK, 3University of Oslo, Oslo, Norway

PDB18

POPULATION ATTRIBUTABLE RISK OF MICROVASCULAR EVENTS ASSOCIATED WITH HBA1C, BLOOD PRESSURE OR WEIGHT IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

 

Heintjes E1, Penning-van Beest FJA2, Parasuraman SV3, Grandy S3, Pollack M3, Herings R1
1PHARMO Institute, Utrecht, The Netherlands, 2PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 3AstraZeneca, Wilmington, DE, USA

PDB19

A SYSTEMATIC REVIEW OF RECENT DATA DESCRIBING THE RISK OF COMPLICATIONS IN TYPE 1 DIABETES MELLITUS PATIENTS

 

Pearson I1, Wolowacz S1, Irving A1, Brockbank J1, Chubb B2, Gundgaard J3, Briggs A4, Davies MJ5
1RTI Health Solutions, Didsbury, Manchester, UK, 2Novo Nordisk Ltd, Crawley, West Sussex, UK, 3Novo Nordisk A/S, Søborg, Denmark, 4University of Glasgow, Glasgow, UK, 5University of Leicester, Leicester, UK

PDB20

SAFETY OF PREOPERATIVE VITAMIN D REPLACEMENT IN MILD PRIMARY HYPERPARATHYROIDISM WITH VITAMIN D DEFICIENCY: A META-ANALYSIS

 

Ravinder P1, Venkat A1, Dev K2
1Long Island University, Brooklyn, NY, USA, 2Sri Krupa Institute of Pharmaceutical Sciences, Gajwel, Andhra Pradesh, India

DIABETES/ENDOCRINE DISORDERS – Cost Studies

PDB21

CHART AUDIT AND BUDGET IMPACT ANALYSIS OF PASIREOTIDE VERSUS SECOND-LINE THERAPIES IN THE TREATMENT OF CUSHING'S DISEASE IN GERMANY

 

Badia X1, Forsythe A2, Stemmer V3, Cummins G4
1IMS Health, Barcelona, Barcelona, Spain, 2Novartis Pharmaceuticals, East Hanover, NJ, USA, 3Novartis Pharma GmbH, Nuremberg, Germany, 4Quintiles Consulting, Hawthorne, NY, USA

PDB22

POTENTIAL BUDGET IMPACT OF LINAGLIPTIN IN FRANCE ESTIMATED FROM CURRENT PATTERN OF DIPEPTIDYL PEPTIDASE 4 INHIBITORS PRESCRIPTIONS

 

Colin X1, Detournay B1, Briand Y2, Delaitre O2
1Cemka, Bourg la Reine, France, 2Boehringer Ingelheim France, Paris, Ile de France, France

PDB23

WITHDRAWN

 

 

PDB24

COST ANALYSIS OF ADDING PREGABALIN OR GABAPENTIN TO USUAL CARE IN THE MANAGEMENT OF COMMUNITY-TREATED PATIENTS WITH PAINFUL DIABETES PERIPHERAL NEUROPATHY IN SPAIN

 

Sicras-Mainar A1, Rejas J2, Navarro-Artieda R3, Planas A4, Collados C5
1Badalona Serveis Assistencials, Badalona, Barcelona, Spain, 2Pfizer España, Alcobendas/Madrid, Spain, 3Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, 4Hospital Municipal de Badalona, Badalona, Barcelona, Spain, 5Pfizer Spain, Alcobendas (Madrid), Spain

PDB25

EVALUATION OF HEALTH CARE COST OF DIABETES BEFORE AND AFTER COUNSELING IN SOUTH INDIAN COMMUNITY SETUP

 

Mateti UV1, Akari S1, Adla N2
1St.Peter's Institute of Pharmaceutical Sciences, Warangal, Andhra Pradesh, India, 2Vaagdevi College of Pharmacy, Warangal, Andhra Pradesh, India

PDB26

EFFECT OF DIABETES DISEASE MANAGEMENT PROGRAMS BASED ON BUNDLED PAYMENT ON CURATIVE HEALTH CARE COSTS IN THE NETHERLANDS

 

Mohnen SM, Molema CC, Baan CA, de Jong-van Til JT, Struijs JN
RIVM (National Institute for Public Health and the Environment), Bilthoven, The Netherlands

PDB27

THE RELATIONSHIP BETWEEN THE PRESENCE OF METABOLIC COMPLICATIONS AND COST COMPONENTS OF TYPE 2 DIABETES MELLITUS PATIENTS IN TURKEY

 

Satman I1, Akalin S2, Ozdemir O3
1Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2The Foundation of Marmara University, School of Medicine, Istanbul, Turkey, 3Yorum Consulting Co. Ltd., Istanbul, Turkey

PDB28

COST OF DISEASE AND ITS RELATIONSHIP WITH DIABETIC COMPLICATIONS IN TURKISH PATIENTS WITH TYPE 2 DIABETES MELLITUS

 

Akalin S1, Satman I2, Ozdemir O3
1The Foundation of Marmara University, School of Medicine, Istanbul, Turkey, 2Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 3Yorum Consulting Co. Ltd., Istanbul, Turkey

PDB29

GLYCEMIC CONTROL AND DIABETES-RELATED HEALTH CARE COSTS IN TYPE 2 DIABETES. A RETROSPECTIVE ANALYSIS BASED ON ADMINISTRATIVE AND CLINICAL DATA

 

Degli Esposti L, Saragoni S, Buda S, Degli Esposti E
CliCon Srl, Ravenna, Italy

PDB30

THE PATTERN AND PRESCRIPTION COST AMONG DIABETIC PATIENTS IN THE HO MUNICIPAL HOSPITAL, VOLTA REGION, GHANA

 

Okotah AN
Ho Municipal Hospital, Accra, Accra, Ghana

PDB31

THE RELATIONSHIP BETWEEN THE COST OF DISEASE AND THE PRESENCE OF OPHTHALMIC COMPLICATIONS IN TYPE 2 DIABETES MELLITUS IS DETERMINED VIA THE CONCOMITANT COMPLICATIONS OTHER THAN OPHTHALMIC COMPLICATIONS

 

Akalin S1, Satman I2, Ozdemir O3
1The Foundation of Marmara University, School of Medicine, Istanbul, Turkey, 2Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 3Yorum Consulting Co. Ltd., Istanbul, Turkey

PDB32

DIABETIC FOOT SYNDROME HOSPITALIZATION COSTS IN POLAND

 

Kasprowicz M1, Lasocha P1, Macioch T1, Hermanowski TR1, Sobol E2, Krakowiecki A1, Karnafel W1
1Medical University of Warsaw, Warsaw, Poland, 2Medical University of Warsaw Central Clinical Hospital, Warsaw, Poland

PDB33

BURDEN OF DISEASE ATTRIBUTABLE TO CLINICAL AND SUBCLINICAL HYPOTHYROIDISM IN THE SPANISH POPULATION

 

Crespo C1, Pérez-Alcántara F1, Polanco C2
1Oblikue Consulting, Barcelona, Spain, 2Merck SL, Madrid, Spain

PDB34

ECONOMIC EVALUATION OF TREATING DIABETES PATIENTS ACCORDING TO GUIDELINES IN SOUTH-WESTERN ONTARIO, CANADA

 

Tarride JE1, Petrella RJ2, O'Reilly D3, Xie F1, reza Nakhai-Pour H1, Blackhouse G4, Goeree R1
1McMaster University, Hamilton, ON, Canada, 2Lawson Health Research Institute, London, ON, Canada, 3PATH Research Institute, McMaster University, Hamilton, ON, Canada, 4Programs for Assessment of Technology in Health (PATH) Research Institute, Hamilton, ON, Canada

PDB35

EVALUATION OF THE LONG TERM ECONOMIC IMPACT OF IMPROVING HBA1C IN TYPE 2 DIABETES PATIENTS IN SAUDI ARABIA

 

Todorova L1, Baabbad R2, Smith-Palmer J3, Al-Mansari A4
1Novo Nordisk International Operations, Zurich, Switzerland, 2King Saud Medical City, Riyadh, Saudi Arabia, 3Ossian Health Economics and Communications, Basel, Switzerland, 4Erfan and Bagedo Hospital, Jeddah, Saudi Arabia

PDB36

AN EVALUATION OF THE LONG-TERM COSTS AND EFFECTS OF A 1% REDUCTION IN HBA1C IN TYPE 2 DIABETES PATIENTS IN MALAYSIA

 

Shafie AA1, Kareem F2, Hussein Z3, Smith-Palmer J4, Hunt B4, Todorova L5
1Universiti Sains Malaysia, Penang, Malaysia, 2Novo Nordisk International Operations, Selangor, Malaysia, 3Hospital Putrajaya, Putrajaya, Malaysia, 4Ossian Health Economics and Communications, Basel, Switzerland, 5Novo Nordisk International Operations, Zurich, Switzerland

PDB37

COST-EFFECTIVENESS OF ADDING TWICE-DAILY EXENATIDE TO BASAL INSULIN IN PATIENTS WITH TYPE 2 DIABETES IN SCOTLAND

 

Varol N1, Wilson BP2, Norrbacka K3, Valentine WJ4, Pollock RF4
1Eli Lilly and Company, Surrey, UK, 2Lilly UK, Hampshire, UK, 3Oy Eli Lilly Finland AB, Helsinki, Finland, 4Ossian Health Economics and Communications, Basel, Switzerland

PDB38

COST-EFFECTIVENESS OF INSULIN DETEMIR IN PEOPLE WITH TYPE 2 DIABETES IN ROMANIA

 

Ionescu–Targoviste C1, Wrona W2, Schubert A3, Niewada M2, Czech M3
1National Institute of Diabetes “Nicolae Paulescu”, Bucharest, Romania, 2HealthQuest Sp z o.o. Sp. k., Warsaw, Poland, 3Novo Nordisk Pharma Sp z.o.o., Warsaw, Poland

PDB39

EVALUATION OF THE LONG-TERM CLINICAL AND ECONOMIC IMPACT OF A 1% HBA1C REDUCTION IN PATIENTS WITH TYPE 2 DIABETES IN INDONESIA

 

Todorova L1, Soewondo P2, Hunt B3, Suastika K4
1Novo Nordisk International Operations, Zurich, Switzerland, 2University of Indonesia, Jakarta, Indonesia, 3Ossian Health Economics and Communications, Basel, Switzerland, 4University of Udayana, Bali, Indonesia

PDB40

THE IMPORTANCE OF HBA1C EVOLUTION IN COST-EFFECTIVENESS MODELING OF TYPE 2 DIABETES MELLITUS (T2DM)

 

Willis M1, He J2, Neslusan C2, Johansen P1, Worbes-Cerezo M3
1The Swedish Institute for Health Economics, Lund, Sweden, 2Janssen Global Services LLC, Raritan, NJ, USA, 3Janssen-Cilag SA, Madrid, Madrid, Spain

PDB41

LONG-TERM EVALUATION OF THE ECONOMIC IMPACT OF REDUCING HBA1C BY 1% IN TYPE 2 DIABETES PATIENTS IN ALGERIA

 

Roca P1, Lamri L2, Belhadj M3, Pollock RF4, Valentine WJ5, Todorova L6
1Novo Nordisk International Operations, Algiers, Algeria, 2University of Algiers, Algiers, Algeria, 3EHU d'Oran, Oran, Algeria, 4Ossian Health Economics and Communications, Basel, Switzerland, 5Ossian Health Economics and Communications, Basel, Basel, Switzerland, 6Novo Nordisk International Operations, Zurich, Switzerland

PDB42

EVALUATING THE CLINICAL AND COST OUTCOMES ASSOCIATED WITH IMPROVING GLYCEMIC CONTROL IN TYPE 2 DIABETES PATIENTS IN INDIA

 

Todorova L1, Shah SN2, Valentine WJ3
1Novo Nordisk International Operations, Zurich, Switzerland, 2Bhatia Hospital, Mumbai, India, 3Ossian Health Economics and Communications, Basel, Basel, Switzerland

PDB43

ECONOMIC EVALUATION OF VILDAGLIPTIN COMPARED TO GLIMEPIRIDE AS ADD-ON TO METFORMIN FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2 PATIENTS IN GREECE

 

Hatzikou M1, Rombopoulos G1, Yfantopoulos J2
1Novartis Hellas, Metamorfosis, Greece, 2National and Kapodistrian University of Athens, Athens, Greece

PDB44

LONG-TERM EVALUATION OF THE ECONOMIC IMPACT OF REDUCING HBA1C BY 1% IN TYPE 2 DIABETES PATIENTS IN MEXICO

 

Todorova L1, González-Gálvez G2, Pollock RF3
1Novo Nordisk International Operations, Zurich, Switzerland, 2Instituto Jalisciense de Investigacion en Diabetes y Obesidad, Guadalajara, Mexico, 3Ossian Health Economics and Communications, Basel, Switzerland

PDB45

COST-EFFECTIVENESS OF VILDAGLIPTIN COMPARED TO GENERIC SULPHONYLUREAS ADDED ON TO METFORMIN FROM THE PORTUGUESE SOCIETAL PERSPECTIVE

 

Calado F1, Gruenberger JB2, Silva-Nunes J3, Carvalho D4
1Novartis, Sintra, Portugal, 2Novartis, Basel, Switzerland, 3Curry Cabral Hospital, Lisboa, Portugal, 4S.
João Hospital / Faculty of Medicine, Porto, Portugal

PDB46

ANTI-DIABETIC DRUGS AND IN-PATIENT ADMISSIONS ATTRIBUTABLE TO DIABETES IN PORTUGAL

 

Gouveia M1, Laires P2, Borges M3, Augusto M4, Martins AP2
1Catholic University of Portugal, Lisbon, Portugal, 2Merck, Sharp & Dohme, Oeiras, Portugal, 3University of Lisbon, Lisbon, Portugal, 4CEA, Católica Lisbon School of Business and Economics, Lisbon, Portugal

PDB47

EFFECTS OF PATIENT-REPORTED NON-SEVERE HYPOGLYCAEMIA ON HEALTH CARE RESOURCE USE AND WORK-TIME LOSS IN SEVEN EUROPEAN COUNTRIES

 

Geelhoed-Duijvestijn PHLM1, Pedersen-Bjergaard U2, Jensen MM3, Östenson CG4
1Haaglanden Medical Centre, The Hague, The Netherlands, 2Hillerød Hospital, Hillerød, Denmark, 3Novo Nordisk Scandinavia AB, København S, Denmark, 4Karolinska Institutet, Stockholm, Sweden

PDB48

HEALTH CARE RESOURCES UTILIZATION AND COSTS ASSOCIATED WITH THE MANAGEMENT OF PATIENTS WITH ACROMEGALY: AN ANALYSIS BASED ON THE RAMQ DATABASE

 

Lachaine J1, Serri O1, Beauchemin C1, Hurry M2, Koch C2
1University of Montreal, Montreal, QC, Canada, 2Novartis Pharmaceuticals Canada, Dorval, QC, Canada

PDB49

COST AND HEALTH CARE RESOURCES UTILIZATION IN THE MANAGEMENT OF CUSHING'S DISEASE: AN ANALYSIS BASED ON THE RAMQ DATABASE

 

Lachaine J1, Beauchemin C1, Koch C2, Hurry M2, Lacroix A3
1University of Montreal, Montreal, QC, Canada, 2Novartis Pharmaceuticals Canada, Dorval, QC, Canada, 3Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM),, Montreal, QC, Canada

PDB50

HEALTH CARE RESOURCE UTILIZATION IN THE MANAGEMENT OF CUSHING DISEASE: AN ANALYSIS FROM SOUTH-WESTERN ONTARIO

 

Petrella RJ1, Van Uum S1, Hurry M2
1Lawson Health Research Institute, London, ON, Canada, 2Novartis Pharmaceuticals Canada, Dorval, QC, Canada

PDB51

RESOURCE UTILIZATION IN THE MANAGEMENT OF ACROMEGALY: AN ANALYSIS FROM SOUTHWEST ONTARIO

 

Petrella RJ1, Van Uum S1, Hurry M2
1Lawson Health Research Institute, London, ON, Canada, 2Novartis Pharmaceuticals Canada, Dorval, QC, Canada

DIABETES/ENDOCRINE DISORDERS – Patient-Reported Outcomes & Patient Preference Studies

PDB52

ADHERENCE: A REAL WORLD RETROSPECTIVE DATABASE STUDY AMONG TYPE 2 DIABETES PATIENTS TREATED WITH LIRAGLUTIDE OR EXENATIDE

 

Maria M1, Carlqvist P2, Langer J3, Bouchard J3
1Evidence Development Ltd., Stockholm, Sockholm, Sweden, 2Heron AB, Stockholm, Stockholm, Sweden, 3Novo Nordisk, Inc., Princeton, NJ, USA

PDB53

PRELIMINARY RESULTS OF A MULTICENTER OBSERVATIONAL STUDY OF TREATMENT COMPLIANCE WITH FREE-COMBINATION VERSUS FIXED COMBINATION TREATMENT IN TYPE II DIABETES MELLITUS PATIENTS IN GREECE (LESS STUDY)

 

Rombopoulos G1, Hatzikou M1, Kossiva E1, Athanasiadis A2, Elisaf M3
1Novartis Hellas, Metamorfosis, Greece, 2Foundation for Economic and Industrial Research (IOBE), Athens, Greece, 3University Hospital of Ioannina, Ioannina, Greece

PDB54

SYSTEMATIC LITERATURE REVIEW OF UTILITY VALUES ASSOCIATED WITH TYPE 2 DIABETES-RELATED COMPLICATIONS

 

Beaudet A1, Clegg JP1, Lloyd A2
1IMS Health, Basel, BS, Switzerland, 2IMS Health, London, UK

PDB55

THE ADAPTATION OF THE INJECTION PEN ASSESSMENT QUESTIONNAIRE FOR USE IN EUROPE – VALIDATION RESULTS FROM A LARGE MULTICENTER STUDY OF RECOMBINANT HUMAN GROWTH HORMONE TREATMENT NAÏVE CHILDREN AND ADULTS

 

Pleil A1, Kimel M2, Wollmann H3
1Pfizer, Inc., San Diego, CA, USA, 2United BioSource Corporation, Bethesda, MD, USA, 3Pfizer, Ltd, Walton Oaks, UK

PDB56

DEVELOPMENT AND VALIDATION OF PATIENT REPORTED ENDPOINTS FOR T2DM

 

Bron M1, Hudgens S2, Stokes J2, Banderas B2, Viswanathan P1, Dabbous O1
1Takeda Pharmaceuticals, Deerfield, IL, USA, 2Adelphi Values, Boston, MA, USA

PDB57

PATIENTS' PREFERENCES FOR ATTRIBUTES OF TYPE 2 DIABETES MEDICATIONS: A CONJOINT ANALYSIS

 

Gelhorn H1, Stringer SM1, Brooks A1, Thompson C1, Monz BU2, Boye KS3, Hach T4, Lund S4, Palencia R2
1United BioSource Corporation, Bethesda, MD, USA, 2Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany, 3Eli Lilly and Company, Indianapolis, IN, USA, 4Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany

PDB58

THE PSYCHOMETRIC PERFORMANCE OF THE EQ-5D, SF-6D AND DIABETES HEALTH PROFILE (DHP-18) IN TYPE 2 DIABETES

 

Mulhern B1, Churchman D2, Meadows K3
1University of Sheffield, Sheffield, UK, 2University of Oxford, Oxford, UK, 3DHP Research & Consultancy Ltd, Banbury, UK

PDB59

CONTENT VALIDITY OF A NEW PATIENT-REPORTED OUTCOME INSTRUMENT TO ASSESS HYPOGLYCEMIA: THE HYPOGLYCEMIA PERSPECTIVES QUESTIONNAIRE

 

Gwaltney C1, Kopenhafer L2, Victor T3, DiBonaventura MD2, Gruenberger JB4, Ong SH5
1Invivodata, Inc., Westerly, RI, USA, 2Kantar Health, New York, NY, USA, 3Kantar Health, Princeton, NJ, USA, 4Novartis, Basel, Switzerland, 5Novartis Pharma AG, Basel, Switzerland

PDB60

PRELIMINARY RESULTS ON THE RELIABILITY AND VALIDITY OF THE WORRY SUBSCALE OF THE HYPOGLYCAEMIC FEAR SURVEY-II FOR ASSESSING THE IMPACT OF FEAR FOR HYPOGLYCEMIA ON THE HEALTH-RELATED QUALITY OF LIFE OF TYPE 2 DIABETES MELLITUS PATIENTS IN SPAIN

 

Font B1, Lahoz R1, Roldan C1, Jódar E2, Álvarez F3, Ávila L4, Palomares R5, Lizan L6
1Novartis Farmaceutica, Barcelona, Spain, 2Hospital Universitario Quirón Madrid, Madrid, Spain, 3Centro de Salud la Calzada II, Gijón, Spain, 4Consultorio Local Almachar, Málaga, Spain, 5Hospital Reina Sofía, Córdoba, Spain, 6Universitat Jaume I, Castellon, Castellon, Spain

PDB61

RESEARCH ON THE INCIDENCE AND COST OF HYPOGLYCEMIA EPISODE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)

 

Zheng Y1, Wu J1, Österle A2
1Tianjin University, Tianjin, China, 2Vienna University of Economics and Business, Vienna, Austria

PDB62

TYPE 2 DIABETES IN RUSSIA: PREVALENCE, RISK FACTORS, AND BURDEN

 

DiBonaventura MD1, Kontsevaya A2, Isherwood G3
1Kantar Health, New York, NY, USA, 2State Research Center for Preventive Medicine, Moscow, Central Federal , Russia, 3Kantar Health, Epsom, Surrey, UK

PDB63

IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE IN ACROMEGALY WITH PASIREOTIDE LAR AND OCTREOTIDE LAR: RESULTS FROM A LARGE, RANDOMIZED, DOUBLE-BLIND PHASE III TRIAL

 

Badia X1, Forsythe A2, Nelson LM3, Coles TM3, McLeod LD3, Webb SM4
1IMS Health, Barcelona, Barcelona, Spain, 2Novartis Pharmaceuticals, East Hanover, NJ, USA, 3RTI Health Solutions, Research Triangle Park, NC, USA, 4Hospital Sant Pau and CIBERER 747, Universitat Autònoma de Barcelona, Barcelona, Spain

PDB64

THE AVOIDANCE OF WEIGHT GAIN IS IMPORTANT FOR ORAL TYPE 2 DIABETES TREATMENTS IN SWEDEN AND GERMANY: A PATIENT PREFERENCE STUDY

 

Mohamed A1, Zhang J1, Johnson FR1, Duprat Lomon I2, Malvoti E2, Ostgren CJ3, Parhofer KG4
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Bristol-Myers Squibb, 92500 Rueil Malmaison , France, 3Linköping University, Linköping, Sweden, 4Klinikum der Universität München, Munich, Germany

PDB65

IMPAIRMENT OF WORK PRODUCTIVITY AND DAILY ACTIVITIES IN TURKISH PATIENTS WITH TYPE 2 DIABETES MELLITUS

 

Satman I1, Akalin S2, Ozdemir O3
1Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2The Foundation of Marmara University, School of Medicine, Istanbul, Turkey, 3Yorum Consulting Co. Ltd., Istanbul, Turkey

DIABETES/ENDOCRINE DISORDERS – Health Care Use & Policy Studies

PDB66

QUANTIFYING THE IMPACT OF POOR GLYCAEMIC CONTROL COMPARED WITH GUIDELINES IN THE TREATMENT OF TYPE 2 DIABETES IN UK CLINICAL PRACTICE

 

McEwan P1, Bennett H2, Bergenheim K3
1HEOR Consulting, Monmouth, Monmouthshire, UK, 2Swansea University, Cardiff, UK, 3AstraZeneca, Mölndal, Sweden

PDB67

DISPARITIES IN DIABETES CARE IN TYPE 2 DIABETICS WITH SCHIZOPHRENIA

 

Cheng JS1, Shih YT2
1Chang Gung University, Kwei-Shan, Tao-Yuan, Taiwan, 2National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan

PDB68

PHYSICIAN BELIEFS ABOUT INSULIN PENS VERSUS VIALS, THERAPY CHOICE FACTORS, AND PATIENT CHARACTERISTICS AMONG ELDERLY TYPE 2 DIABETES PATIENTS

 

Eby E1, Frois C2, Guerin A3, Boggs JA1, Nyhuis A1, Swindle R1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Analysis Group, Ltee., Montreal, QC, Canada

PDB69

DIFFUSION OF NEW TECHNOLOGIES POST REIMBURSEMENT – MONITORING THE USE OF LIRAGLUTIDE IN PRIMARY CARE

 

O'Leary A1, Usher C1, Mulhall C1, Barry M2
1National Centre for Pharmacoeconomics, Dublin 8, Ireland, 2St. James's Hospital, Dublin, Ireland, Ireland

PDB70

CHARACTERISTICS OF LONG-ACTING SOMATOSTATIN (SSA) USE IN ACROMEGALY IN THE NETHERLANDS

 

Bezemer ID1, Penning FJA1, Brulais S2, Verduyn CSC3, Herings RMC1
1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Ipsen pharma, Boulogne-Billancourt, France, 3Mapi Consultancy, Houten, The Netherlands

PDB71

PATIENT ACCESS, HBA1C KNOWLEDGE, AND HEALTH OUTCOMES AMONG TYPE 2 DIABETES PATIENTS IN BRAZIL

 

Annunziata K1, Pomerantz D1, DiBonaventura MD2, Follador W3
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, New York, NY, USA, 3Sanofi, São Paulo , São Paulo , Brazil

PDB72

MAIN FACTORS ASSOCIATED TO COSTS OF TYPE 2 DIABETES MELLITUS (DM2) CARE IN SPAIN. A SYSTEMATIC REVIEW OF THE 2001-2011 LITERATURE

 

Gonzales Segura D1, Paz S2, Lizan L2
1Almirall, Barcelona, Barcelona, Spain, 2Outcomes 10, Castellon, Castellon, Spain

PDB73

OBESITY AND FREQUENT HYPOGLYCEMIA IN EUROPEAN TYPE 2 DIABETES PATIENTS

 

Vietri J1, Isherwood G2, Le Pautremat V3, Eschwège EM4
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, Epsom, Surrey, UK, 3Kantar Health, Montrouge, France, 4INSERM, Villejuif, France

PDB74

EFFECTIVE HEALTH CARE BUDGET PLANNING FOR INNOVATIVE DRUGS IN DIABETES TREATMENT IN TURKEY; FROM THE PERSPECTIVE OF THE SOCIAL SECURITY INSTITUTION (SSI)

 

Kececioglu S, Ulus P, Cukadar F
Boehringer Ingelheim Turkey, ISTANBUL, TURKEY, Turkey

PDB75

ASSOCIATION BETWEEN HYPOGLYCAEMIC EVENTS AND SHORT-TERM DISABILITY AMONG PATIENTS WITH DIABETES BEING TREATED WITH INSULIN USING A CLAIMS DATABASE APPROACH

 

Young T1, Shao W2, Weng W1, Bouchard JR2
1Novo Nordisk Inc, Princeton, NJ, USA, 2Novo Nordisk, Inc., Princeton, NJ, USA

PDB76

CLINICAL EFFECTIVENESS OF INCREASED PHYSICAL ACTIVITY IN TYPE 2 DIABETES, SYSTEMATIC REVIEW

 

Herrmann KH1, Semlitsch T2, Jeitler K3, Schuermann C1, Janzen T1, Hemkens LG4, Matyas E2, Pignitter N2, Siebenhofer-Kroitzsch A5, Horvath K6
1IQWiG, Cologne, Germany, 2EBM Review Center, Graz, Austria, 3EBM Review Center, Graz , Austria, 4Stanford University, Stanford, CA, USA, 5Goethe-Universität Frankfurt am Main Zentrum für Gesundheitswissenschaften, Frankfurt am Main, Germany, 6EBM Review Center, Graz, Germany

PDB77

CHARACTERISTICS OF PATIENTS WITH DIABETES IN SOUTHWESTERN ONTARIO, CANADA

 

Petrella RJ1, Tarride JE2, O'Reilly D3, Xie F2, Goeree R2
1Lawson Health Research Institute, London, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 3PATH Research Institute, McMaster University, Hamilton, ON, Canada

PDB78

DETERMINANTS OF TREATMENT CHANGES OF ORAL ANTI/DIABETIC DRUGS IN THE UNITED KINGDOM

 

Maguire A1, Mitchell B2
1United BioSource Corporation, London, UK, 2Eli Lilly and Company, Indianapolis, IN, USA

PDB79

TREATMENT PATTERNS OF ORAL ANTI-DIABETIC DRUGS IN THE UNITED KINGDOM

 

Maguire A1, Mitchell B2
1United BioSource Corporation, London, UK, 2Eli Lilly and Company, Indianapolis, IN, USA

SESSION IV – TUESDAY, 6 NOVEMBER
SET-UP: Tuesday, 6 November, 14:45 – 15:00
POSTER DISPLAY HOURS: Tuesday, 6 November,15:00-19:00
POSTER AUTHOR DISCUSSION HOUR: Tuesday, 6 November, 18:00 – 19:00
DISMANTLE: Tuesday, 6 November, 19:00

SYSTEMIC DISORDERS/CONDITIONS – Clinical Outcomes Studies

PSY1

CARDIOVASCULAR AND CONGENITAL SAFETY EVALUATION OF ANTIOBESITY AGENTS, INCLUDING TOPIRAMATE: A PHARMACOVIGILANCE ANALYSIS OF THE ADVERSE EVENT REPORTING SYSTEM

 

Ali AK
University of Florida, Gainesville, FL, USA

PSY2

PRELIMINARY VALIDATION OF COLLECT SCALE: A CO-MORBIDITY ASSESSMENT TOOL FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA

 

Giraldo P1, Lopez A2, Rios E3, Gonzalez-Grande I4, Roset M5, Castro-Gomez A6, De La Serna J7, Carbonell F8
1Hospital Universitario Miguel Servet, Zaragoza, Spain, 2Hospital Universitari Valle d'Hebron, Barcelona, Spain, 3Hospital Virgen de Valme, Sevilla, Spain, 4Roche Farma, S.A., Madrid, Spain, 5IMS Health, Barcelona, Spain, 6Roche, Madrid, Spain, 7Hospital Universitario 12 de Octubre, Madrid, Spain, 8Consorci Hospital General Universitari Valencia, Valencia, Spain

PSY3

DISEASE ACTIVITY INDICES (DAIS) IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

 

Wyrwich K1, Winnette R2, Oglesby A3, Narayanan S4
1United BioSource Corporation, Bethesda, MD, USA, 2United BioSource Corporation, London, UK, 3GlaxoSmithKline, Research Triangle Park, NC, USA, 4Human Genome Sciences, Inc., Rockville, MD, USA

PSY4

LENALIDOMIDE OR BORTEZOMIB FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM): A COMPARATIVE EFFECTIVENESS ANALYSIS USING INDIRECT STATISTICAL TECHNIQUES

 

Kaura S1, Dranitsaris G2
1Celgene Corporation, Summit, NJ, USA, 2Augmentium Pharma Consulting, Toronto, ON, Canada

PSY5

COMPARING BRENTUXIMAB VEDOTIN OVERALL SURVIVAL DATA TO STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL) POST-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)

 

Woods B1, Thompson J1, Barcena L1, Liu Y2, Huang H2, Martinez C3
1Oxford Outcomes, Oxford, UK, 2Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, 3Institute of Hematology and Oncology, Barcelona, Spain

SYSTEMIC DISORDERS/CONDITIONS – Cost Studies

PSY6

ECONOMIC EFFICIENCY OF FERRIC CARBOXYMALTOSE TO TREAT OR PREVENT IRON DEFICIENCY ANEMIA: VALUE TO THE PORTUGUESE HOSPITALS

 

Ferreira D, Silva M, Vandewalle B, Félix J
Exigo Consultores, Alhos Vedros, Portugal

PSY7

SOCIETAL BURDEN ASSOCIATED WITH NEUROPATHIC PAIN IN EUROPE

 

Ruiz L1, O'Hara J1, deCourcy J1, Higgins V2, Piercy J1
1Adelphi Real World, Bollington, UK, 2Adelphi Real World, New York, NY, USA

PSY8

NUMBER NEEDED TO TREAT (NNT) AND COST ESTIMATION TO ACHIEVE A MAJOR MOLECULAR RESPONSE (MMR) IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS IN GREECE

 

Hatzikou M1, Geitona M2, Gigantes S3, Harhalakis N3
1Novartis Hellas, Metamorfosis, Greece, 2University of Peloponnese, Korinth, Greece, Greece, 3Evangelismos Hospital, Athens, Greece

PSY9

REAL-LIFE COST-ANALYSES OF CHRONIC LOW-BACK PAIN PATIENTS WITH NEUROPATHIC PAIN COMPONENTS IN DENMARK

 

Sætterstrøm B1, Poulsen PB2, Olsen J1, Strand M2, Schiøttz-Christensen B3
1University of Southern Denmark, Odense, Denmark, 2Pfizer Denmark, Ballerup, Denmark, 3Aarhus Rheumatologic Clinic, Aarhus, Denmark

PSY10

AN INDIRECT COMPARISON OF ICATIBANT AND FOUR OTHER THERAPIES FOR THE SYMPTOMATIC TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA TYPES I AND II

 

Helbert M1, Pang F2, Alvarez-Reyes M3, Roskell NS4, Diwakar L5
1Manchester Royal Infirmary, Manchester, Greater Manchest, UK, 2Shire Human Genetic Therapies, Basingstoke , UK, 3Shire Human Genetic Therapies, Basingstoke, Hampshire, UK, 4RTI Health Solutions, Manchester, UK, 5University of Birmingham, and Department of Immunology, Heartlands Hospital, Birmingham, West Midlands , UK

PSY11

SWEDISH ADAPTATION OF CZECH PHARMACOECONOMIC COMPARISON OF TREATMENTS IN HAEMOPHILIA PATIENTS WITH INHIBITORS

 

Ericsson Å1, Mesterton J2, Hedner U3
1Novo Nordisk Scandinavia AB, Malmö, Sweden, 2Quantify Research, Stockholm, Sweden, 3Lund University, Malmö, Sweden

PSY12

THE COST OF TREATING CHRONIC MYELOID LEUKEMIA (CML) IN GREECE

 

Geitona M1, Hatzikou M2, Gigantes S3, Konstantinidou M2, Solakidi A4, Harhalakis N3
1University of Peloponnese, Korinth, Greece, Greece, 2Novartis Hellas, Metamorfosis, Greece, 3Evangelismos Hospital, Athens, Greece, 4University of Peloponnese, Corinth, Greece

PSY13

PILOT COST STUDY OF CHRONIC MIELOID LEUKEMIA THERAPY

 

Kamusheva M1, Georgieva S2, Stoimenova A1, Petrova G1
1Medical University, Faculty of Pharmacy, Sofia, Bulgaria, 2Medical University, Faculty of Pharmacy, Alexandrovska Hospital, Sofia, Bulgaria

PSY14

LONG-TERM MEDICAL COSTS AND LIFE EXPECTANCY OF ACUTE MYELOID LEUKAEMIA: A PROBABILISTIC DECISION MODEL

 

Wang HI1, Howell D1, Smith A1, Roman E1, Aas E2
1University of York, York, UK, 2University of Oslo, Oslo, Norway

PSY15

IMPACT OF CHRONIC IMMUNE-MEDIATED INFLAMMATORY DISEASES ON WORK PRODUCTIVITY: LITERATURE REVIEW

 

Granados D1, Depont F2, Chevreul K3
1Abbott Laboratories, Rungis, France, 2SC Partners, Paris, France, France, 3Unité de Recherche Clinique Economie de la santé d'Ile-de-France, Paris, France

PSY16

EFFECT OF THE ANTI-TUMOR NECROSIS FACTOR ADALIMUMAB ON WORK PRODUCTIVITY IN PATIENTS WITH CHRONIC IMMUNE-MEDIATED INFLAMMATORY DISEASES: LITERATURE REVIEW

 

Granados D1, Depont F2, Chevreul K3
1Abbott Laboratories, Rungis, France, 2SC Partners, Paris, France, 3Unité de Recherche Clinique Economie de la santé d'Ile-de-France, Paris, France

PSY17

ESTIMATING THE DIRECT COSTS OF PATIENTS TREATED WITH ELTROMBOPAG IN THE FRENCH SETTING

 

Khellaf M1, Colin X2, Leclerc-Teffahi S3, Levy-Bachelot L3
1Referral Center for autoimmune cytopenia – Henri MONDOR University Hospital, Creteil, France, 2Cemka-Eval, Bourg-la-Reine, France, 3GlaxoSmithKline, Marly-le-Roi Cedex , France

PSY18

CLINICAL OUTCOMES, RESOURCE UTILIZATION AND TREATMENT COST OF MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOIDE LEUKEMIA IN A REAL WORLD SETTING: SINGLE-CENTER EXPERIENCE

 

Almeida A1, Ferreira D2, Rabiais S2, Félix J2
1Instituto Português de Oncologia de Lisboa, Lisboa, Portugal, 2Exigo Consultores, Alhos Vedros, Portugal

PSY19

A COST-CONSEQUENCE ANALYSIS OF PATIENT SELF-MANAGEMENT VERSUS PHYSICIAN-MANAGED MONITORING OF LONG-TERM ORAL ANTICOAGULATION THERAPY IN CANADA

 

Lepage S1, Beauchemin C1, de Denus S1, Verret L2, Nguyen A2, Tremblay S2, Brouillette D2, Lachaine J1
1University of Montreal, Montreal, QC, Canada, 2Montreal Heart Institute, Montreal, QC, Canada

PSY20

COST-EFFECTIVENESS OF PROPHYLAXIS WITH AN ANTI-INHIBITOR COMPLEX CONCENTRATE IN PATIENTS WITH HAEMOPHILIA AND INHIBITORS: RESULTS FROM PRO-FEIBA STUDY

 

Gringeri A1, Leissinger C2, Cortesi PA3, Cristiani M4, Fusco F5, Mantovani LG6
1Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico/University of Milan, Milano, Italy, 2Tulane University, New Orleans, LA, USA, 3University of Milano - Bicocca, Monza, Italy, 4Charta fondation, milano, Italy, 5Scuola Superiore Sant'Anna Univesity, Pisa, Italy, 6Federico II University of Naples, Naples, Italy

PSY21

COST-EFFECTIVENESS OF POSACONAZOLE VERSUS FLUCONAZOLE IN THE PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH GRAFT-VERSUS-HOST DISEASE (GVHD) IN TURKEY

 

Akan H1, Ozdemir O2
1Ankara University Faculty of Medicine, Ankara, Turkey, 2Yorum Consulting Co. Ltd., Istanbul, Turkey

PSY22

A COST-EFFECTIVENESS ANALYSIS OF PARECOXIB IN THE MANAGEMENT OF POST-OPERATIVE PAIN IN THE GREEK HEALTH CARE SETTING

 

Athanasakis K1, Petrakis I2, Karabela P1, Vitsou E2, Pimenidou A2, Kyriopoulos J1
1National School of Public Health, Athens, Greece, 2Pfizer Hellas, Athens, Greece

PSY23

PHARMACOECONOMIC ASPECTS OF DEXKETOPROFEN TROMETAMOL AND DICLOFENAC IN ACUTE POST-TRAUMATIC PAIN

 

Ryazhenov VV, Gorokhova SG
I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PSY24

ECONOMIC EVALUATION OF OPIOID SUBSTITUTION TREATMENT (OST) IN GREECE

 

Geitona M1, Carayanni V2, Petratos P1, Androutsou L1
1University of Peloponnese, Korinth, Greece, Greece, 2Technological Educational Institute of Athens, Athens, Greece, Greece

PSY25

ETANERCEPT IN EARLY RHEUMATOID ARTHRITIS: ECONOMIC EVALUATION FROM THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

 

Takemoto M1, Fernandes RA1, Fujii RK2, Mould J3, Tang B3
1ANOVA - Knowledge Translation, Rio de Janeiro, RJ, Brazil, 2Pfizer, Inc., São Paulo, São Paulo, Brazil, 3Pfizer, New York, NY, USA

PSY26

COST-EFFECTIVENESS OF HEMATOPOIETIC STEM CELL MOBILIZATION STRATEGIES IN MULTIPLE MYELOMA AND LYMPHOMA PATIENTS IN CZECH REPUBLIC

 

Vitova V1, Tichopad A1, Sturdikova M2, Kucera Z2, Lysak D3, Koristek Z4
1CEEOR s.r.o., Prague, Czech Republic, 2Sanofi-Aventis, Prague, Czech Republic, 3FN Plzen, Plzen, Czech Republic, 4FN Brno, Brno, Czech Republic

PSY27

A COST-EFFECTIVENESS COMPARISON OF ICATIBANT AND C1-ESTERASE INHIBITOR CONCENTRATE FOR THE SYMPTOMATIC TREATMENT OF ACUTE ATTACKS OF TYPES I AND II HEREDITARY ANGIOEDEMA IN THE UK SETTING

 

Helbert M1, Pang F2, Alvarez-Reyes M3, Pearson I4, Wolowacz S4, Diwakar L5
1Manchester Royal Infirmary, Manchester, Greater Manchest, UK, 2Shire Human Genetic Therapies, Basingstoke , UK, 3Shire Human Genetic Therapies, Basingstoke, Hampshire, UK, 4RTI Health Solutions, Didsbury, Greater Manchest, UK, 5University of Birmingham, and Department of Immunology, Heartlands Hospital, Birmingham, West Midlands, UK

PSY28

COST-EFFECTIVENESS OF FEBUXOSTAT IN MANAGING HYPERURICEMIA IN GOUT PATIENTS IN SPAIN

 

Cuesta M, Pérez Alcántara F, Brosa M
Oblikue Consulting, Barcelona, Spain

PSY29

TITLE: THE CHALLENGE OF CONDUCTING A PROSPECTIVE ECONOMIC EVALUATION OF A PHARMACOGENETIC TEST

 

Thompson A1, Payne K1, Roberts SA1, Newman W2, Elliott RA3, Tricker K2
1University of Manchester, Manchester, UK, 2University of Manchester and Central Manchester NHS Foundation Trust, Manchester, UK, 3University of Nottingham, Nottingham, UK

PSY30

COST-EFFECTIVENESS OF USTEKINUMAB IN THE MANAGEMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN MEXICO

 

Valencia-Mendoza A1, Hernández-Garduño A2, Puig A3
1Janssen de Mexico, Mexico, DF, D.F., Mexico, 2Janssen de Mexico, Mexico, D.F., Mexico, 3Janssen Pharmaceuticals, Raritan, NJ, USA

SYSTEMIC DISORDERS/CONDITIONS – Patient-Reported Outcomes & Patient Preference Studies

PSY31

ASSOCIATION BETWEEN TERIPARATIDE ADHERENCE AND HEALTH CARE UTILIZATION AND COSTS IN REAL WORLD U.S. HIP FRACTURE PATIENTS

 

Johnston SS1, Zhao Y2, Smith D1, McMorrow D3, Krohn K4, Krege JH2
1Thomson Reuters, Washington, DC, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Thomson Reuters, Cambridge, MA, USA, 4Lilly USA, LLC, Indianapolis, IN, USA

PSY32

MEASURING THE LEVEL & IMPACT OF NEUROPATHIC PAIN IN THE EU

 

O'Hara J1, Ruiz L1, de Courcy J1, Higgins V2, Piercy J1
1Adelphi Real World, Bollington, UK, 2Adelphi Real World, New York, NY, USA

PSY33

ITEM REDUCTION AND ASSESSMENT OF MEASUREMENT PROPERTIES OF THE HUNTER SYNDROME – FUNCTIONAL OUTCOMES FOR CLINICAL UNDERSTANDING SCALE (HS-FOCUS)

 

Wiklund I1, Raluy M1, Chen WH2, Muenzer J3, Pelletier N4, Fang J4, Whiteman DAH5
1United BioSource Corporation, London, UK, 2United BioSource Corporation, Bethesda, MD, USA, 3University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4Shire Human Genetic Therapies, Lexington, MA, USA, 5Shire AG, Eysins, Switzerland

PSY34

UNDERSTANDING DISEASE PRESENTATION AND PATIENT-REPORTED AND ECONOMIC IMPACT OF HERPES ZOSTER (HZ) AND POST-HERPETIC NEURALGIA (PHN): FINDINGS FROM THE ZOSTER QUALITY OF LIFE (ZQOL) STUDY

 

Carroll S1, Gater A2, Abetz L2, Demuth D3, Smith F3, Mannan A4
1Sanofi Pasteur MSD, Maidenhead, Berkshire, UK, 2Adelphi Values, Bollington, Cheshire, UK, 3Adelphi Real World, Bollington, Cheshire, UK, 4Sanofi Pasteur MSD, Maidenhead, UK

PSY35

ASSESSMENT OF THE MOST BOTHERSOME SYMPTOMS AND IMPACTS REPORTED BY PATIENTS WITH CHRONIC LOW BACK PAIN

 

Ramasamy A1, Blum SI1, Liedgens H2, Martin ML3, McCarrier KP3, Quintanar-Solares M4, Argoff C5, Freynhagen R6, Patrick DL7, Wallace MS8
1Forest Research Institute, Jersey City, NJ, USA, 2Grünenthal GmbH, Aachen, Germany, 3Health Research Associates, Inc., Seattle, WA, USA, 4Health Research Associates, Mountlake Terrace, WA, USA, 5Albany Medical College, Albany, NY, USA, 6Benedictus Krankenhaus Tutzing, Tutzing, Germany, 7University of Washington, Seattle, WA, USA, 8University of California San Diego, La Jolla, CA, USA

PSY36

CHANGES IN PAIN INTENSITY AND HEALTH RELATED QUALITY OF LIFE (QOL) IN PATIENTS WITH PERIPHERAL NEUROPATHIC PAIN AFTER A SINGLE TREATMENT OF 8% CAPSAICIN PATCH – RESULTS FROM A SWEDISH 12 WEEK PROSPECTIVE OBSERVATIONAL STUDY

 

Hansson P1, Magnusson K2, Persson CA2
1Department of Anaesthesiology and Intensive Care, Stockholm, Sweden, 2Astellas Pharma A/S, Kastrup, Denmark

PSY37

PATIENT-REPORTED OUTCOME (PRO) ASSESSMENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

 

Wyrwich K1, Winnette R2, Oglesby A3, Narayanan S4
1United BioSource Corporation, Bethesda, MD, USA, 2United BioSource Corporation, London, UK, 3GlaxoSmithKline, Research Triangle Park, NC, USA, 4Human Genome Sciences, Inc., Rockville, MD, USA

PSY38

SPONTANEOUS AND PROBED DISEASE-DEFINING CONCEPTS IDENTIFIED THROUGH CONCEPT ELICITATION INTERVIEWS IN CHRONIC LOW BACK PAIN

 

McCarrier KP1, Blum SI2, Martin ML1, Liedgens H3, Quintanar-Solares M4, Ramasamy A2, Argoff C5, Freynhagen R6, Patrick DL7, Wallace MS8
1Health Research Associates, Inc., Seattle, WA, USA, 2Forest Research Institute, Jersey City, NJ, USA, 3Grünenthal GmbH, Aachen, Germany, 4Health Research Associates, Mountlake Terrace, WA, USA, 5Albany Medical College, Albany, NY, USA, 6Benedictus Krankenhaus Tutzing, Tutzing, Germany, 7University of Washington, Seattle, WA, USA, 8University of California San Diego, La Jolla, CA, USA

PSY39

VALIDATION OF THE LUPUS IMPACT TRACKER (LIT), A PATIENT-REPORTED OUTCOME (PRO) TOOL, IN A PROSPECTIVE MULTICENTER LONGITUDINAL STUDY OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS

 

Jolly M1, Kosinski M2, Garris CP3, Oglesby AK3
1Rush University, Chicago, IL, USA, 2QualityMetric Incorporated, Lincoln, RI, USA, 3GlaxoSmithKline, RTP, NC, USA

PSY40

HEALTH-RELATED QUALITY OF LIFE AND ANNUAL DIRECT MEDICAL COST OF PATIENTS WITH HAEMOPHILIA B IN FRANCE: THE EQOFIX STUDY

 

Polack B1, Calvez T2, Claeyssens S3, Chambost H4, Derlon A5, Goudemand J6, Rothschild C7, Maurel F8, Woronoff-Lemsi MC9
1Department of Hematology, CHU Grenoble, Grenoble Cedex, France, 2Inserm & UPMC, Paris, France, 3Regional Haemophilia Treatment Center, Toulouse Cedex, France, 4Regional Haemophilia Treatment Center, Marseille Cedex 5, France, 5Regional Haemophilia Treatment Center, CAEN Cedex, France, 6Regional Haemophilia Treatment Center, Lille Cedex, France, 7Regional Haemophilia Treatment Center, Paris Cedex 1, France, 8IMS Health, 92807 Puteaux Cedex, France, 9Department of Pharmacy, Besançon Cedex, France

PSY41

SYMPTOMS AND IMPACTS ASSOCIATED WITH ANAEMIA OF CHRONIC KIDNEY DISEASE (CKD)

 

Wiklund I1, Eriksson D1, Cooper O1, van Nooten F2, Holmstrom S3
1United BioSource Corporation, London, United Kingdom, 2Astellas Pharma Europe B.V., Leiderdorp, Netherlands, 3Astellas Pharma Global Development, Leiderdorp, Netherlands

PSY42

EFFECTIVENESS AND SAFETY OF ANTI-TNF AGENTS IN TREATMENT OF MODERATE TO SEVERE PSORIASIS VULGARIS: RESULTS OF WORK PRODUCTIVITY AND DAILY ACTIVITY IMPAIRMENT

 

Koc E1, Ozarmagan G2, Alper S3, Ozgoztasi O4, Tekin NS5, Balci DD6, Onsun N7, Tuzun Y8, Atakan N9, Ozturkcan S10, Kokturk A11
1Gulhane Military Medical School, Ankara, Turkey, 2Istanbul University Istanbul School of Medicine, Istanbul, Turkey, 3Ege University Faculty of Medicine, Izmir, Turkey, 4Gaziantep University Faculty of Medicine, Gaziantep, Turkey, 5Zonguldak Karaelmas University Faculty of Medicine, Zonguldak, Turkey, 6Mustafa Kemal University Faculty of Medicine, Hatay, Turkey, 7Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey, 8Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey, 9Hacettepe University Faculty of Medicine, Ankara, Turkey, 10Celal Bayar University Faculty of Medicine, Manisa, Turkey, 11Mersin University Faculty of Medicine, Mersin, Turkey

SYSTEMIC DISORDERS/CONDITIONS – Health Care Use & Policy Studies

PSY43

UTILIZATION OF PAIN MEDICATIONS IN PATIENTS WITH CHRONIC LOWER BACK PAIN WHO INITIATED DULOXETINE OR STANDARD OF CARE FOR THE MANAGEMENT OF PAIN

 

Peng X1, Wu N2, Chen SY2, Yu X2, Andrews JS1, Novick D3
1Eli Lilly and Company, Indianapolis, IN, USA, 2United BioSource Corporation, Lexington, MA, USA, 3Eli Lilly and Company, Windlesham, Surrey, UK

PSY44

A COST EFFECTIVENESS MODEL FOR THE MYELOPLASTIC DISEASE IN GREECE. AZACITIDINE VERSUS CONVENTIONAL CARE REGIMENS

 

Yfantopoulos J1, Kritikou P2
1National and Kapodistrian University of Athens, Athens, Greece, 2University of Athens, Athens, Greece

PSY45

SOCIAL ECONOMIC BURDEN AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RARE DISEASES IN EUROPE (BURQOL-RD PROJECT). SPANISH RESULTS

 

Linertová R1, López-Bastida J2, Serrano-Aguilar P3, Posada-de-la-Paz M4
1Fundación Canaria de Investigación y Salud (FUNCIS), Las Palmas de Gran Canaria, Spain, 2Universidad de Castilla - La Mancha, Talavera de la Reina, Toledo, Spain, 3Canary Islands Health Service, Santa Cruz de Tenerife, Canary Islands, Spain, 4Instituto de Salud Carlos III, Madrid, Spain

PSY46

IMPACT OF THE NEUROPATHIC PAIN COMPONENT ON QUALITY OF LIFE IN PATIENTS WITH LOW BACK PAIN

 

Obradovic M, Falke D, Steigerwald I, Liedgens H
Grünenthal GmbH, Aachen, Germany

PSY47

THE RELATIONSHIP BETWEEN PAIN SEVERITY AND HEALTH UTILITIES: INFORMING CLINICAL TRIAL DESIGN TO SUBSTANTIATE VALUE

 

Suponcic S1, DiBonaventura MD1, Victor T2
1Kantar Health, New York, NY, USA, 2Kantar Health, Princeton, NJ, USA

PSY48

DEVELOPING A NATIONAL OUTCOMES TREATMENT REGISTRY FOR HEPATITIS C PATIENTS IN THE ERA OF THE DAAS

 

O'Leary A1, Norris S2, Bergin C3, Kieran J4, Walsh C4, Barry M5
1National Centre for Pharmacoeconomics, Dublin 8, Ireland, 2St. James hospital, Dublin, Ireland, 3St. James Hospital, Dublin, Ireland, 4Trinity College Dublin, Dublin, Ireland, 5St. James's Hospital, Dublin, Ireland, Ireland

PSY49

TREATMENT PATTERNS IN PSORIATIC ARTHRITIS (PSA) PATIENTS NEWLY INITIATED ON NON-BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS)

 

Curtis J1, Gauthier G2, Hiscock R2, Zhang F3
1University of Alabama at Birmingham, Birmingham, AL, USA, 2Analysis Group, Inc., Montreal, QC, Canada, 3Celgene Corporation, Summit, NJ, USA



15th Annual European Congress Index Page